Introduction {#s1}
============

*PTEN* (phosphatase and tensin homolog) is the second most commonly mutated tumor suppressor gene in human cancer ([@bib8]) and has a central role in multicellular morphogenesis ([@bib49]; [@bib31]; [@bib15]). While PTEN antagonizes the phosphoinositol 3-kinase (PI3K)/AKT pathway via its N-terminal phosphatase domain ([@bib8]), three-dimensional (3D) multicellular assembly was unaffected by forced variation of PI3K activity in colorectal organotypic model systems ([@bib31]; [@bib47]). The *PTEN* domain structure includes an N-terminal phosphatase domain, a C2 domain, a C-terminal tail and a PDZ-binding domain. The C2 domain binds to membrane phospholipids by inserting a hydrophobic (CBR3) loop into the membrane bilayer and thereby provides a scaffold for juxtamembrane signaling ([@bib39]). Furthermore, the PTEN C2 domain regulates polarized migration ([@bib64]), multicellular morphology ([@bib40]; [@bib32]) and has an important but poorly understood tumor suppressor function ([@bib10]).

Within complex systems, protein scaffolding enhances signaling efficiency by assembly of spatially distinct subcellular complexes for different cellular tasks ([@bib82]; [@bib62]). The PTEN C2 domain binds the plasma membrane and interacts with the scaffold protein β-Arrestin1 ([@bib42]) that in turn binds and suppresses ARHGAP21 ([@bib2]), a member of a highly conserved class of RhoGAPs ([@bib6]; [@bib1]). ARHGAP21 regulates the small GTPases, Cdc42 ([@bib18]) and RhoA ([@bib2]). These GTPases have overlapping, complementary functions required for mitotic spindle orientation and consequent control of the cell division axis, cytokinetic furrow positioning, daughter cell size and tissue morphogenesis ([@bib53]). Both Cdc42 and RhoA drive actin nucleation and cortical stiffening ([@bib46]; [@bib20]) required for spindle orientation ([@bib34]). Furthermore, Cdc42 crosstalk with protein kinase c zeta \[PRKCZ\] ([@bib58]; [@bib19]) localizes force generators within the cell cortex that act via astral microtubules to orientate the spindle ([@bib27]). ARHGAP21 has high GAP activity for Cdc42 ([@bib18]) and its Pac-1 homologue regulates multicellular patterning in C. elegans by spatial regulation of Cdc42 ([@bib1]; [@bib35]).

Here, we investigate PTEN spatiotemporal coordination of mammalian glandular morphogenesis through conserved juxtamembrane β-Arrestin1-ARHGAP21 interactions, using 3D colorectal cancer (CRC) model systems. To substantiate physiological relevance of these processes, we also investigate their role in morphogenesis of 3D multicellular organoids isolated from normal colon.

Results {#s2}
=======

PTEN regulates β-Arrestin1 membrane localization {#s2-1}
------------------------------------------------

β-Arrestin1 scaffolds juxtamembrane signaling networks ([@bib36]), binds ARHGAP21 ([@bib2]) and governs PTEN catalytic and noncatalytic functions ([@bib42]). To ascertain whether PTEN regulates membrane-associated β-Arrestin1 and ARHGAP21, we conducted expression and simple fractionation studies in PTEN-expressing \[Caco-2 and HCT116\] and -deficient \[Caco-2 Sh*PTEN* (Sh*PTEN*) and *PTEN* ^-/-^ HCT116 (*PTEN* ^-/-^)\] cells. We found near-significant or significant differences of total lysate β-Arrestin1 and ARHGAP21 between PTEN-expressing and -deficient cells \[Caco-2 *vs* Sh*PTEN* ([Figure 1A,B](#fig1){ref-type="fig"}) and HCT116 vs *PTEN* ^-/-^ cells ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"})\]. To infer subcellular localization *of* β-Arrestin1 and ARHGAP21, we performed membrane fractionation studies and normalized each protein's densitometry value against its total lysate level, to investigate relative proportions of β-Arrestin1 and ARHGAP21 associated with membrane. We found greater β-Arrestin1 but lower ARHGAP21 levels in Caco-2 than in Sh*PTEN* membrane fractions ([Figure 1C,D](#fig1){ref-type="fig"}). As β-Arrestins are known to localize to activated lysophosphatidic acid receptors \[LPARs\] ([@bib80]; [@bib41]) that are expressed in Caco-2 and HCT116 cell membranes ([@bib83]), we investigated effects of PTEN on lysophosphatidic acid (LPA)-induced membrane recruitment of β-Arrestin1. We found greater LPA-mediated membrane enrichment of β-Arrestin1 in Caco-2 and HCT116 cells than in PTEN-deficient Sh*PTEN* or *PTEN ^-/-^* HCT116 (*PTEN ^-/-^)* subclones ([Figure 1E,F](#fig1){ref-type="fig"}; [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}). We next used confocal microscopy to determine PTEN effects on β-Arrestin1 subcellular distribution in whole cells. We expressed the β-Arrestin1-mCherry fusion protein and mCherry only controls in PTEN-expressing and -deficient cells. We assessed colocalization with Alexa 488-labeled wheat germ agglutinin (WGA), a widely used fluorescent probe for cell and Golgi complex membranes ([@bib13]) by confocal microscopy. β-Arrestin1-mCherry was predominantly cytosolic in vehicle only (VO)-treated cells, in accord with cytosolic accumulation of unlabelled β-Arrestin1 in fractionation studies. On treatment with LPA, the β-Arrestin1*-*mCherry fusion protein colocalized with WGA at the plasma membrane in PTEN*-*expressing Caco-2 and HCT116 control cells ([Figure 1G](#fig1){ref-type="fig"}; [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Line scanning analysis revealed overlap of β-Arrestin1-mCherry and Alexa 488 fluorescence signals in plasma membrane peaks in PTEN-expressing Caco-2 and HCT116 cells after LPA treatment ([Figure 1G](#fig1){ref-type="fig"}; [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). While LPA had limited effects in Sh*PTEN* cells that have residual low level PTEN ([Figure 1G](#fig1){ref-type="fig"}), this treatment had no effects on β-Arrestin1*-*mCherry subcellular distribution in *PTEN*-null (*PTEN* ^-/-^) cells ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). mCherry only did not localize at the plasma membrane (data shown for control PTEN-expressing HCT116 and *PTEN* ^-/-^ cells only; [Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). To exclude a non-specific effect of PTEN on ligand-mediated protein translocation to the cell membrane, we investigated 1,25(OH)~2~D~3~-mediated membrane localization of E-Cadherin ([@bib61]) in Caco-2 and Sh*PTEN* cells. We found that 1,25(OH)~2~D~3~ treatment induced equivalent E-Cadherin translocation to the plasma membrane in PTEN-expressing and -deficient cells, compared to control VO treatment (data not shown). Collectively, these findings show that PTEN functions within a regulatory scaffolding network that couples β-Arrestin1 to ARHGAP21 at the plasma membrane.

![PTEN enhances membrane recruitment of β-Arrestin1.\
(**A,B**) Total lysate β-Arrestin1 and ARHGAP21 expression in ShPTEN vs Caco-2 (control). GAPDH loading control; β-Arrestin1 = 0.78 ± 0.06; p=NS (0.08); ARHGAP21 = 1.29 ± 0.05;\*p=0.03. (**C**) Cytosol and membrane localization of β-Arrestin1 and ARHGAP21 in control Caco-2 or Caco-2 ShPTEN (ShPTEN) cells. E-Cadherin and HSP90 used as cell membrane or cytosol markers. (**D**) Summary β-Arrestin1 and ARHGAP21 membrane ADU in ShPTEN cells vs Caco-2 control. Membrane values are normalized against total lysate ADU values for each protein (β-Arrestin1 = 0.82 ± 0.03 \*p\<0.05; ARHGAP21 = 1.48 ± 0.05 \*\*p\<0.01). (**E**) β-Arrestin1 expression in membrane fractions of control Caco-2 and ShPTEN cells after treatment. (**F**) Summary fold change of membrane β-Arrestin1 after LPA (+) or VO \[vehicle only(-)\] treatment shown in (**E**) ;Caco-2 (+) vs (-)=1.74 ± 0.09; \*\*p\<0.01; ShPTEN (+) vs ShPTEN (-)=0.97 ± 0.08 vs 0.66 ± 0.07;\*p\<0.05 values expressed as fold change relative to Caco-2 (-) control. ShPTEN (-) vs Caco-2 (-)=0.66 ± 0.07;\*p\<0.05; ShPTEN (+) vs Caco-2 (+)=0.97 ± 0.08 vs 1.74 ± 0.09;\*\*p\<0.01. Green bars indicate ShPTEN cells. (**G**) Plasma membrane localization of the β-Arrestin1-mCherry fusion protein in Caco-2 control (top two panels) or ShPTEN (bottom two panels) after VO (-) or LPA (+) treatment. Red and green fluorescence emitted by m-Cherry and Alexa 488 labels correspond to β-Arrestin1 and WGA, respectively. Note WGA localization to plasma membranes and Golgi apparatus. Colocalization of β-Arrestin1 and WGA at the plasma membrane revealed by composite yellow signal in Merge, Z-stack images and by overlap of fluorescence intensity curves in line scans. Horizontal yellow bars indicate focal plane. All experiments in triplicate. Analyses by Student's paired t test or ANOVA with Tukey post hoc test. White scale bar 20 µm. Molecular weights indicated by arrows in blots.\
10.7554/eLife.24578.010Figure 1---source data 1.Source data for [Figure 1B](#fig1){ref-type="fig"}.\
10.7554/eLife.24578.011Figure 1---source data 2.Source data for [Figure 1D](#fig1){ref-type="fig"}.\
10.7554/eLife.24578.012Figure 1---source data 3.Source data for [Figure 1F](#fig1){ref-type="fig"}.](elife-24578-fig1){#fig1}

PTEN controls Cdc42-dependent epithelial morphogenesis through β-Arrestin1-ARHGAP21 interactions {#s2-2}
------------------------------------------------------------------------------------------------

Within signaling scaffolds, β-Arrestin1 regulates monomeric GTPases ([@bib3]) and orchestrates cytoskeletal rearrangements ([@bib24]). We investigated β-Arrestin1-ARHGAP21 coregulation of Cdc42, mitotic spindle orientation and morphogenesis in 3D organotypic model systems. SiRNA knockdown (KD) of β-Arrestin1 in control PTEN-expressing Caco-2 cells suppressed Cdc42 activation as assessed by Cdc42-GTP levels in cell lysates on Western blots ([Figure 2A,B](#fig2){ref-type="fig"}). In contrast, siRNA KD of ARHGAP21 enhanced Cdc42 activation in PTEN-deficient cells ([Figure 2C,D](#fig2){ref-type="fig"}). During normal organotypic 3D glandular morphogenesis, mitotic spindle planes are orientated at approximately right angles to gland centres (GCs) by Cdc42-dependent mechanisms. Conversely, Sh*PTEN* cells show deficiencies of these processes ([@bib31]; [@bib15]; [@bib32]). In 3D Caco-2 cultures, SiRNA β-Arrestin1 KD suppressed *Cdc42*-GTP ([Figure 2E,F](#fig2){ref-type="fig"}), induced mitotic spindle misorientation and abnormal multilumen formation ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}). Conversely, ARHGAP21 KD enhanced Cdc42-GTP ([Figure 2G,H](#fig2){ref-type="fig"}), restored mitotic spindle orientation and promoted single lumen formation in 3D Sh*PTEN* cultures ([Figure 2G](#fig2){ref-type="fig"}, [Figure 2---figure supplements 3](#fig2s3){ref-type="fig"} and [4](#fig2s4){ref-type="fig"}). Because of the previously reported relationship between ARHGAP21 and RhoA ([@bib42]), we assessed relationships between β-Arrestin1, ARHGAP21 and RhoA. We found that activation of RhoA related directly to β-Arrestin1 and inversely to ARHGAP21 expression. β-Arrestin1 and RhoA-GTP were suppressed, while ARHGAP21 expression was enhanced by PTEN knockdown (data for RhoA-GTP not shown). Taken together, these data indicate that PTEN regulates β-Arrestin1-ARHGAP21 interactions to control GTPase signaling, mitotic spindle orientation and 3D multicellular morphology.

![PTEN controls morphogenesis through Cdc42/β-Arrestin1/ARHGAP21 interactions.\
(**A,B**) SiRNA β-Arrestin1 knockdown (KD) suppresses Cdc42*-*GTP in Caco-2 and HCT116 cells (fold changes = 0.62 ± 0.09;\*p=0.03 and 0.51 ± 0.03;\*\*p=0.005 respectively. (**C,D**) SiRNA ARHGAP21 KD enhances Cdc42-GTP in Caco-2 Sh*PTEN* (Sh*PTEN*) and HCT116 *PTEN* ^-/-^ (*PTEN* ^-/-^) cells (fold change = 1.41 ± 0.09 and 1.51 ± 0.11, respectively; \*p=0.02 for each. Cdc42-GTP ADU was normalized against total Cdc42. (**E**) SiRNA β-Arrestin1 KD suppresses Cdc42-GTP signal intensity, impairs spindle orientation and inhibits single lumen formation. High-power (HP) spindle views (orange border) enlarge areas within white rectangles and show orientation angles (interrupted white arrows) of spindle planes (double-headed solid white arrows) toward gland centres (GCs). Normal spindle planes are orientated at approximately 90^0^ angles relative to gland centres \[GCs\] ([@bib30]). Summary SiRNA effects on spindle angles relative to GCs are shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. (**F**) Summary SiRNA effects on Cdc42-GTP intensity shown in (**E**) - control vs *β-Arrestin1* SiRNA = 24.67 ± 1.45 vs 14.33 ± 0.88 AI units; \*\*p=0.004. *β-Arrestin1* KD also suppresses single central lumen formation in 3D Caco-2 cultures (E; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). (**G**) SiRNA *ARHGAP21* KD increases Cdc42*-*GTP signal intensity (**H**), rescues spindle orientation (**G**, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) and central lumen formation in Sh*PTEN* 3D cultures (**G**, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). (**H**) Cdc42-GTP, control vs SiRNA *ARHGAP21* KD in Sh*PTEN* cultures = 10.67 ± 0.67 vs=19.67 ± 0.88 AI units; \*\*p\<0.01. Assays at 4 days of culture. Imaging Cdc42-GTP \[green\], pericentrin (*PCN*) \[red\], α-Tubulin \[green\], ARHGAP21 \[red\], PRKCZ \[red\], β-Arrestin1 \[red\] and DAPI \[blue\]. All experiments conducted in triplicate. All analyses by paired Student's t test. Scale bars 20 µm. Molecular weights indicated by arrows in blots.\
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PTEN promotes β-Arrestin1 and ARHGAP21 interactions through its C2 domain {#s2-3}
-------------------------------------------------------------------------

β-Arrestin1 has previously been shown to bind the PTEN C2 domain directly and modulate PTEN function ([@bib42]). To investigate PTEN regulation of β-Arrestin1-ARHGAP21 interactions, we conducted co-immunoprecipitation (CoIP) studies and normalized β-Arrestin1-associated ARHGAP21 against total ARHGAP21 densitometry values in cell lysates. Here, we show greater β-Arrestin1-associated ARHGAP21 levels in PTEN-expressing Caco-2 or HCT116 cells versus Sh*PTEN* or *PTEN*^-/-^ cells or IgG negative controls ([Figure 3A,B](#fig3){ref-type="fig"}). To investigate involvement of *PTEN *catalytic and noncatalytic domains in these processes, we conducted transient expression studies of GFP-labeled full-length wild type (wt) *PTEN* or mutants ([Figure 3C](#fig3){ref-type="fig"}), in *PTEN-*deficient cells. Mutants included full-length *PTEN* with a mutation at the CBR3 membrane-binding loop within the C2 domain (*PTEN-*MCBR3), full-length phosphatase-dead (*PTEN* C124S-based) constructs with mutations in key C-terminal phosphorylation sites, namely *PTEN* C124S-T383A (CS-T383A) and *PTEN* C124S-A4 (CS-A4 with S380A, T382A, T383A and S385A mutations combined). CS-T383A has been proposed to contain an unmasked C2 domain ([@bib63]) that effectively binds β-Arrestin1 while CS-A4 lacks β-Arrestin1 binding capacity ([@bib42]). We also used the isolated *PTEN* C2 domain (C2) and a membrane-binding mutant of the C2 domain (C2-MCBR3). We found that expression of C2 enhanced β-Arrestin1-associated ARHGAP21 levels in CoIPs conducted in Sh*PTEN* ([Figure 3D,E](#fig3){ref-type="fig"},) and *PTEN* ^-/-^ cells ([Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}). Conversely, C2-MCBR3 had no significant effect on β-Arrestin1-associated ARHGAP21 levels in CoIPs ([Figure 3D,E](#fig3){ref-type="fig"}, [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}). β-Arrestin1-associated ARHGAP21 levels were normalized against total *A*RHGAP21 expression in cell lysates. Collectively, these findings indicate that the membrane-binding function of PTEN is important for scaffolding ARHGAP21 and β-Arrestin1.

![PTEN C2 enhances β-Arrestin1-ARHGAP21 binding.\
(**A**) β-Arrestin1-ARHGAP21 CoIPs in PTEN-expressing and -deficient cells. β-Arrestin1-associated ARHGAP21 shown in top panel against a constant β-Arrestin1 bait signal (second panel). IgG-negative controls. Total β-Arrestin1 and ARHGAP21 in lysates and *GAPDH* loading controls shown in lower three panels. (**B**) Summary β-Arrestin1-associated ARHGAP21 in PTEN-deficient (colored bars) vs PTEN-expressing cells (clear bars). Values normalized against total ARHGAP21 = 0.35 ± 0.01;\*\*p\<0.01 (Sh*PTEN*) and 0.39 ± 0.02;\*\*p\<0.01 (*PTEN ^-/\ -^* cells), respectively. (**C**) Schematic of GFP-labeled *PTEN* constructs used (top to bottom - wild type (wt) *PTEN; PTEN* - MCBR3 membrane binding mutant; catalytically inactive *PTEN* C124S; *PTEN* C124S - A4 (CS-A4) and *PTEN* C124S -T383A (CS-T383A) mutants that lack or retain β-Arrestin1 binding capacity, respectively ([@bib42]), C2 and the C2-MCBR3 membrane binding mutant. (**D**) β-Arrestin1-associated ARHGAP21 in Sh*PTEN* cells after transfection with GFP-labeled-EV control vs*-* C2 or -C2-MCBR3 (top panel). β-Arrestin1 bait signal shown in second panel. Total β-Arrestin1 and ARHGAP21 in lysates shown in third and fourth panels. Expression of GFP-labeled C2, C2-MCBR3 and EV and *GAPDH* loading controls shown in two lowest panels. (**E**) Summary fold change of β-Arrestin1-associated ARHGAP21 *vs* EV control; C2 = 2.51 ± 0.08;\*\*p\<0.01 or C2-MBCR3 = 1.03 ± 0.06; p=NS. β-Arrestin1-associated ARHGAP21 normalized against total ARHGAP21 in lysate. (**F**) Proximity ligation assay (PLA) of β-Arrestin1 interactions with PTEN constructs (red fluorescence) in *PTEN* ^-/-^ cells. Top row - GFP-labeled CS-T383A, CS-A4, C2, C2-MCBR3; Bottom row - positive control - HCT116 cells; negative control - *PTEN* ^-/-^ cells transfected with GFP only. (**G**) β-Arrestin1-ARHGAP21 interactions. Top row *PTEN* ^-/-^ cells transfected with GFP-labeled full-length *PTEN*, -*PTEN*-MCBR3, -C2 and -C2-MCBR3; Bottom row - positive control - HCT116 cells; negative control - *PTEN* ^-/-^ cells transfected with GFP only. Scale bars - 20 µm; Molecular weights indicated by arrows in blots.\
10.7554/eLife.24578.034Figure 3---source data 1.Source data for [Figure 3B](#fig3){ref-type="fig"}.\
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We then used an intramolecular bioluminescence resonance energy transfer (BRET)-based PTEN biosensor ([@bib43]; [@bib52]) to test if the full-length C124S C-terminal phosphorylation mutants ([Figure 3C](#fig3){ref-type="fig"}) that have different β-Arrestin1 binding capacities ([@bib42]), display different conformations. The biosensor contains PTEN sandwiched between the energy donor Renilla luciferase (Rluc) and the energy acceptor YFP. Changes in the BRET signal depend on the relative distance and orientation of the donor and acceptor proteins within the fusion and therefore provide readout for conformational change of PTEN in live cells ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Wild-type (wt) *PTEN*, CS-T383A and CS-A4 mutants in the Rluc-*PTEN*-YFP construct produced different BRET signals ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These findings show that the phosphatase-dead mutants do indeed adopt different conformations, which is consistent with differences in β-Arrestin1*-*binding capacity. We further investigated protein-protein interactions in vivo using sensitive proximity ligation assays \[PLA\] ([@bib76]). We expressed *PTEN* phosphatase-dead mutants or C2 domain constructs in *PTEN* ^-/-^ cells. We found prominent PLA signals for PTEN-β-Arrestin1 interactions in *PTEN* ^-/-^ cells expressing either *PTEN* CS-T383A or the intact C2 domain. Conversely, *PTEN*^-/-^ cells expressing *PTEN* CS-A4 or C2-MCBR3 mutants showed markedly reduced levels of these interaction signals. PTEN-β-Arrestin1 interaction PLA signals in HCT116 and GFP-only transfected *PTEN ^-/-^* cells were used as positive and negative controls, respectively ([Figure 3F](#fig3){ref-type="fig"}; [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). These findings indicate that PTEN-β-Arrestin1 interactions can occur independently of PTEN phosphatase activity. Next, we investigated effects of PTEN on β-Arrestin1-ARHGAP21 interactions. Transfection of *PTEN* ^-/-^ cells with GFP-labeled-wt *PTEN* or -C2 domain enhanced β-Arrestin1-ARHGAP21 interactions compared to cells transfected with *PTEN*-MCBR3 or C2-MCBR3. β-Arrestin1-ARHGAP21 interaction signals in HCT116 or GFP-only transfected *PTEN* ^-/-^ cells were used as positive and negative controls, respectively. ([Figure 3G](#fig3){ref-type="fig"}; [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). Collectively, these data implicate the PTEN C2 domain in phosphatase-independent binding of β-Arrestin1 and in promoting β-Arrestin1-ARHGAP21 interactions.

PTEN promotes β-Arrestin1 and ARHGAP21 membrane recruitment through its C2 domain {#s2-4}
---------------------------------------------------------------------------------

To explore effects of the isolated PTEN C2 domain on membrane recruitment of β-Arrestin1 or ARHGAP21, we conducted expression, fractionation and CoIP assays in *PTEN*-deficient cells. Expression of the C2 domain enhanced total β-Arrestin1 and suppressed that of ARHGAP21 in *PTEN-*deficient cell lysates while C2-MCBR3 had no significant effects ([Figure 4A--C](#fig4){ref-type="fig"}; [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}--[3](#fig4s3){ref-type="fig"}). C2 expression also enriched β-Arrestin1 and suppressed ARHGAP21 in membrane fractions of *PTEN*-deficient colorectal cell lines ([Figure 4D--F](#fig4){ref-type="fig"}; [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Membrane fraction values were normalized against total expression of each protein in lysate. Furthermore, expression of C2 but not C2-MCBR3 also increased β-Arrestin1-associated ARHGAP21 levels in *PTEN-*deficient cell membrane fractions. β-Arrestin1-associated ARHGAP21 levels were normalized against total ARHGAP21 in the membrane fraction ([Figure 4G--J](#fig4){ref-type="fig"}). In *PTEN ^-/-^* cells, expression of *C2* and full-length *PTEN* had greater effects on β-Arrestin1-associated ARHGAP21 levels than *PTEN-*MCBR3, C2-MCBR3 or control ([Figure 4I,J](#fig4){ref-type="fig"}). *PTEN-*MCBR3 had small but significant effects on β-Arrestin1-associated ARHGAP21 levels in excess of control ([Figure 4I,J](#fig4){ref-type="fig"}). Taken together, these data indicate that PTEN enhances β-Arrestin1 membrane recruitment and β-Arrestin-ARHGAP21 interactions, predominantly through its membrane-binding C2 domain.

![PTEN regulation of juxtamembrane β-Arrestin1 and ARHGAP21.\
(**A**) shows total β-Arrestin1 and ARHGAP21 expression in Caco-2 Sh*PTEN* cell lysates (top two panels) after *PTEN* C2 (**C2**), C2-MCBR3 or EV control transfections. Expression levels of transfected GFP-labelled proteins and β-Actin loading controls shown in lower two panels. (**B**) indicates summary fold changes of total β-Arrestin*1;* C2 = 1.23 ± 0.02; \*\*p\<0.01; MCBR3 = 1.07 ± 0.02; \[MCBR3 vs control = NS\]. (**C**) shows respective fold changes of ARHGAP21; C2 = 0.8 ± 0.02; \*\*p\<0.01; MCBR3 = 0.95 ± 0.03; \[MCBR3 vs control = NS; all values in ADU\]. (**D**) Effects of transfections on cytosol and membrane β-Arrestin1 and ARHGAP21 in Caco-2 *ShPTEN* (Sh*PTEN*) cells (top two panels). Expression levels of transfected GFP-labelled proteins and E-Cadherin and HSP90 membrane and cytosolic markers shown in lower three panels. (**E, F**) Fold change of β-Arrestin1 and ARHGAP21 expression induced in the membrane fraction. (**E**) β-Arrestin1, C2 = 1.25 ± 0.05; \*p=0.04 and (**F**) ARHGAP21* =* 0.53 ± 0.09; \*p=0.03. β-Arrestin1 and ARHGAP21 ADU values normalized against total lysate ADU for each protein. (**G**) β-Arrestin1-associated ARHGAP21 induced in Sh*PTEN* membrane fractions by C2, C2-MCBR3 vs EV control transfections (top panel). β-Arrestin1 bait signal shown in second panel. Total β-Arrestin1 and ARHGAP21 in lysates shown in third and fourth panels. Expression of GFP-labeled C2, C2-MCBR3, EV and E-Cadherin membrane marker shown in lower three panels. (**H**) Fold changes of β-Arrestin1-associated ARHGAP21 normalized against total ARHGAP21 in the membrane fraction (ADU) - C2 = 6.27 ± 0.51; \*\*\*p\<0.001; MCBR3 = 1.25 ± 0.15; \[MCBR3 *vs* control = NS\]. (**I**) β-Arrestin1-associated ARHGAP21 ADU after expression of C2, C2-MCBR3, wt *PTEN* or *PTEN*-MCBR3 vs EV control in *PTEN ^-/-^* cell membrane fractions (top panel). β-Arrestin1 bait signal, total lysate expression of each protein, expression of GFP-labelled EV or C2 domain constructs and E-Cadherin membrane marker shown in lower five panels. (**J**) Summary fold changes of β-Arrestin1-associated ARHGAP21 normalized against total membrane ARHGAP21; C2 = 7.33 ± 0.64; C2-MCBR3 = 2.5 ± 0.35; *PTEN* = 12.93 ± 0.19; *PTEN* MCBR3 = 3.15 ± 0.21 ADU; control vs C2 or *PTEN*, \*\*\*p\<0.001; control vs C2-MCBR3 (NS). Control vs *PTEN*-MCBR3 = \*p\<0.05. Analyses by ANOVA, Tukey post hoc or Student's paired test. Molecular weights indicated by arrows in blots.\
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PTEN controls mitotic spindle orientation and 3D morphogenesis by regulation of β-Arrestin1 {#s2-5}
-------------------------------------------------------------------------------------------

To investigate PTEN coordination of morphogenic processes through its C2 domain, we conducted 3D organotypic culture studies. We found greater expression and membrane localization of β-Arrestin1 in 3D control PTEN-expressing Caco-2 cultures compared to Sh*PTEN* cultures ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), in agreement with our biochemical analysis. Conversely, ARHGAP21 immunoreactivity was lower in control Caco-2 compared to Sh*PTEN* 3D cultures ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). We have shown previously that the abnormal Sh*PTEN* 3D phenotype can be rescued by expression of the *PTEN* C2 domain ([@bib32]). Here, we show that the GFP-tagged *PTEN* C2 domain enhances β-Arrestin1 membrane enrichment ([Figure 5C,D](#fig5){ref-type="fig"}), rescues mitotic spindle orientation ([Figure 5E,F](#fig5){ref-type="fig"}) as well as apical membrane alignment and single lumen morphology ([Figure 5E](#fig5){ref-type="fig"}; [Figure 5---figure supplements 3](#fig5s3){ref-type="fig"} and [4](#fig5s4){ref-type="fig"}) in 3D Sh*PTEN* cultures. These effects were not observed in Sh*PTEN* cultures expressing control GFP or C2-MCBR3-GFP ([Figure 5C--F](#fig5){ref-type="fig"}; [Figure 5---figure supplements 3](#fig5s3){ref-type="fig"} and [4](#fig5s4){ref-type="fig"}). To investigate any potential for *PTEN* ShRNA off-target effects, we investigated effects of full-length ShRNA-resistant *PTEN* (ShR *PTEN*) on the integrated Sh*PTEN* 3D morphology phenotype. We show that expression of ShR *PTEN* rescued defective morphogenesis of 3D Sh*PTEN* cultures ([Figure 5---figure supplements 5](#fig5s5){ref-type="fig"} and [6](#fig5s6){ref-type="fig"}). Collectively, these studies show that the membrane-bound PTEN C2 domain coordinates multicellular gland assembly by β-Arrestin1 membrane recruitment, mitotic spindle orientation, apical membrane alignment and lumen formation.

![PTEN controls mitotic spindle orientation and 3D morphogenesis by noncatalytic regulation of *β-Arrestin1*.\
(**A**) β-Arrestin1 and (**B**) ARHGAP21 immunofluorescence intensity in 3D control Caco-2 and Sh*PTEN* cultures. (**C**) Effects of C2 vs C2-MCBR3 expression on membrane β-Arrestin1 immunoreactivity in Sh*PTEN* cultures. (**D**) Summary cell membrane β-Arrestin1 immunoreactivity AI; EV control vs C2 vs C2-MCBR3 = 9.0 ± 2.08 vs 23.3 ± 1.20 vs 6.33 ± 1.67 AI;\*\*p\<0.01, control vs C2-MCBR3 = NS. (**E**) Effects of C2 vs C2-MCBR3 expression on spindle orientation. High-power (HP) spindle views (orange border) enlarge areas within white rectangles and show orientation angles (interrupted white arrows) of spindle planes (double-headed solid white arrows) toward gland centres (GCs). (**F**) Summary spindle angles relative to GCs in 3D Sh*PTEN* cultures after transfection (● -- Control = 32.08 ± 5.5^0^ vs ● - C2 = 65.72 ± 4.1^0^; \*\*p\<0.01 *vs* ● - MCBR3 = 29.1 ± 4.4^0^; \[MCBR3 *vs* control = NS\], One-way ANOVA; \*\*p\<0.01, Tukey post hoc test. Imaging - DAPI \[blue\], β-Arrestin1 (**A,C**) red, ARHGAP21, (**B**) \[red\], GFP \[green\] and α*-Tubulin* (**E**) \[cyan\]. Scale bars = 20 µm.\
10.7554/eLife.24578.063Figure 5---source data 1.Source data for [Figure 5D](#fig5){ref-type="fig"}.\
10.7554/eLife.24578.064Figure 5---source data 2.Source data for [Figure 5F](#fig5){ref-type="fig"}.](elife-24578-fig5){#fig5}

PTEN controls 3D Caco-2 morphogenesis by noncatalytic coupling of β-Arrestin1, ARHGAP21 and Cdc42 {#s2-6}
-------------------------------------------------------------------------------------------------

Precise spatiotemporal coordination of Cdc42 activity is central to multicellular morphogenesis ([@bib50]). To investigate PTEN non-catalytic regulation of Cdc42 via β-Arrestin1 and ARHGAP21, we conducted transfection and peptide inhibitor studies. Expression of the catalytically inactive *PTEN* CS-T383A construct that binds β-Arrestin1 but not the *PTEN CS-A4* binding-defective mutant, enhanced Cdc42*-*GTP levels in *PTEN* ^-/-^ cells ([Figure 6A,B](#fig6){ref-type="fig"}). While Cdc42 can be inhibited by ARHGAP21 ([@bib17]), competitive β-Arrestin1 binding to the GAP domain can release the active GTPase from ARHGAP21 inhibition ([@bib2]). To investigate the specific role of β-Arrestin1-ARHGAP21 interactions on Cdc42-dependent 3D morphogenesis, we used a cell-permeant 24-mer peptide analogue of the ARHGAP21 GAP domain that was designed to disrupt the β-Arrestin1-ARHGAP21 interaction ([Figure 6C](#fig6){ref-type="fig"}) ([@bib2]). Here, we show that treatment with this β-Arrestin1-ARHGAP21 peptide binding inhibitor (pep24) but not a scrambled control peptide attenuated the association between β-Arrestin1 and ARHGAP21, resulting in lower levels of β-Arrestin1-associated ARHGAP21 ([Figure 6D,E](#fig6){ref-type="fig"}; [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Treatment by pep24 also suppressed Cdc42 activation in Caco-2 ([Figure 6F,G](#fig6){ref-type="fig"}) and HCT116 cells ([Figure 6---figure supplements 3](#fig6s3){ref-type="fig"} and [4](#fig6s4){ref-type="fig"}). Furthermore, pep24 treatment induced dysmorphogenesis of 3D Caco-2 cultures characterized by mitotic spindle misorientation ([Figure 6H](#fig6){ref-type="fig"}, [Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}), apical membrane misalignment, aberrant epithelial configuration and loss of single central lumen formation ([Figure 6I](#fig6){ref-type="fig"}, [Figure 6---figure supplement 6](#fig6s6){ref-type="fig"}). Taken together, these data show that PTEN controls 3D morphogenesis by non-catalytic C2 domain scaffolding of β-Arrestin1-ARHGAP21 interactions and release of Cdc42 from ARHGAP21 inhibition.

![PTEN morphogenic functions mediated by β-Arrestin1, ARHGAP21 and Cdc42.\
(**A**) Effects of *PTEN* CS-A4 or *PTEN* CS-T383A vs EV control on *Cdc42* - GTP levels in *PTEN* ^-/-^ cells. (**B**) indicates fold change of Cdc42-GTP vs EV control; CS-A4 = 0.92 ± 0.16;p=NS; CS-T383A = 1.64 ± 0.11; \*\*p=0.008. (**C**) Schematic of ARHGAP21 showing the β-Arrestin1-binding domain, the pep24 peptide-binding inhibitor and control peptide sequences ([@bib2]). Effects of pep24 vs control peptide (pep) on β-Arrestin1-ARHGAP21 binding (**D,E**) and Cdc42-GTP (**F,G**) in Caco-2 cells. (**E**) indicates fold change of β-Arrestin1-associated ARHGAP21 ADU in Caco-2 cells after pep24 vs control peptide treatment = 0.63 ± 0.02; \*\*p=0.003. (**G**) indicates fold change of Cdc42-GTP in Caco-2 cells after pep24 vs control peptide treatment = 0.48 ± 0.05; \*\*p=0.01. Treatment effects on spindle orientation (**H**) and lumenogenesis (**I**) in 3D Caco-2 cultures. Imaging for pericentrin (*PCN*) \[red\]; PRKCZ \[red\]; α-Tubulin \[green\], DAPI for nuclear DNA \[blue\] and bright-field (BF) imaging of lumen outlines. Spindle planes indicated by double-headed white arrows in Merge (**H**). Analyses by ANOVA, Tukey's post hoc test. Scale bar - 20 µm. Molecular weights indicated by arrows in blots.\
10.7554/eLife.24578.076Figure 6---source data 1.. Figure 6B -Cdc42-GTP after transfection - source data\
10.7554/eLife.24578.077Figure 6---source data 2.[Figure 6E](#fig6){ref-type="fig"} - Peptide inhibitor treatment effects on Beta Arrestin1:ARHGAP21 binding in Caco-2\
10.7554/eLife.24578.078Figure 6---source data 3.[Figure 6G](#fig6){ref-type="fig"} Peptide inhibitor treatment effects on Cdc42-GTP in Caco-2](elife-24578-fig6){#fig6}

β-Arrestin1-ARHGAP21 interactions are essential for self-assembly of normal colorectal organoids {#s2-7}
------------------------------------------------------------------------------------------------

To avoid any compromise of experimental interpretation by intrinsic Caco-2 cancer cell mutations, we investigated our key observations from cell culture experiments in organoids formed from primary normal murine colon cells ([@bib11]). In this study, we cultured colonic crypt progenitor epithelium in Matrigel supplemented with growth factors as previously described ([@bib70]). By these methods, we generated colorectal organoids with appropriate mitotic spindle orientation, apical membrane alignment, luminogenesis and epithelial organization, in 3D cultures ([Figure 7A--C](#fig7){ref-type="fig"}). To investigate the role of β-Arrestin1-ARHGAP21 interactions on colorectal homeostasis, we assessed effects of pep24 vs control peptide treatment on 3D organoid morphogenesis. Here, we show that pep24 treatment perturbed mitotic spindle orientation, disrupted 3D glandular morphology and lumen formation in normal colorectal organoids ([Figure 7A--C](#fig7){ref-type="fig"}). Conversely, control peptide treatment had no discernible effect on 3D glandular morphology ([Figure 7A--C](#fig7){ref-type="fig"}). Collectively, these findings highlight a significant role for β-Arrestin1-ARHGAP21 interaction in multicellular morphogenesis of normal colorectal epithelium.

![β-Arrestin1-ARHGAP21 binding is essential for morphogenesis of normal colorectal organoids.\
(**A**) Effects of pep24 vs control peptide (pep) on multicellular morphogenesis of normal colorectal epithelium. Imaging - apical actin marker FITC-labeled phalloidin \[green\], DAPI for nuclear DNA \[blue\] and FITC-labeled α-Tubulin \[green\]. Spindle orientation indicated by double-headed white arrows. (**B**) Summary spindle angles in 3D colorectal organoids after treatment (n = 30 per treatment group) ●Control peptide = 68.47 ± 5.37^0^ vs ●pep24 = 31.13 ± 3.20^0^; \*\*\*p\<0.001. (**C**) Summary data represent percentage glandular colorectal organoids with single central lumens after treatment; control peptide = 80.00 ± 5.77% vs pep24 = 36.67 ± 3.3%;\*p=0.039; (n = 10 organoids per treatment group in triplicate). Student's t test. Scale bar 20 µm.\
10.7554/eLife.24578.084Figure 7---source data 1.Figure 7B Spindle angles in organoids - souce data.\
10.7554/eLife.24578.085Figure 7---source data 2.Figure 7C Single central lumen formation in organoids - source data.](elife-24578-fig7){#fig7}

Discussion {#s3}
==========

Scaffolding proteins have unique properties for assembling target molecules into cooperative networks within subcellular compartments ([@bib66]) to control diverse biological functions ([@bib60]; [@bib22]; [@bib29]; [@bib73]). β-Arrestin1 acts as a molecular scaffold for G-protein-coupled receptors \[GPCRs\] ([@bib45]), the largest family of signaling receptors. Key GPCRs enhance β-Arrestin1 recruitment to the plasma membrane ([@bib80]; [@bib41]; [@bib16]), activate PTEN ([@bib75]; [@bib69]) and promote PTEN-β-Arrestin1 interactions ([@bib42]). β-Arrestin1 also suppresses ARHGAP21 ([@bib2]) that is independently recruited to the plasma membrane by ADP-ribosylation factor 1 \[ARF-1\] ([@bib37]). In this study, we investigated PTEN coregulation of β-Arrestin1 and ARHGAP21. We found greater β-Arrestin1 levels in lysates of PTEN-expressing HCT116 cells than in the isogenic *PTEN-*null (*PTEN* ^-/-^) subclone and near-significant differences in corresponding PTEN-expressing and -deficient Caco-2 cells. While the precise mechanisms of this effect remain unclear, *PTEN* mutation or deficiency and changes in β-Arrestin1 expression levels characterize various human cancers ([@bib8]; [@bib21]).

As well as protein abundance, stoichiometry and post-translational targeting machinery modulate the assembly of spatially restricted scaffolding complexes ([@bib5]). LPAR is a lysophosphatidic acid (LPA) activated GPCR that couples heterotrimeric G proteins, to control membrane recruitment of β-Arrestin1 ([@bib80]; [@bib41]), GTPase activity ([@bib79]) and cell polarization processes ([@bib54]). To investigate these phenomena, we assessed spontaneous and LPA-mediated cell membrane localization of β-Arrestin1 and ARHGAP21 in subcellular fractions of PTEN-expressing and -deficient cells. We found proportionately greater differences of constitutive and LPA-mediated β-Arrestin1 membrane localization in PTEN-expressing Caco-2 vs PTEN-deficient Sh*PTEN* cells, indicative of PTEN involvement in β-Arrestin1 membrane recruitment. Similarly, LPA promoted greater β-Arrestin1 membrane localization in PTEN-expressing HCT116 cells than in *PTEN* ^-/-^ cells. In both cell types, we found reciprocal differences of ARHGAP21 membrane localization, consistent with β-Arrestin1-mediated suppression ([@bib2]). To investigate PTEN effects on β-Arrestin1 plasma membrane recruitment in whole cells, we used confocal microscopy to track the spatial distribution of transfected β-Arrestin1-mCherry against plasma membrane localization of Alexa 488-labeled WGA. Line scans of fluorescence intensities across image focal planes and high-resolution confocal z-stack reconstructions ([@bib23]) revealed that PTEN enhanced LPA-mediated β-Arrestin1*-*mCherry colocalization with Alexa 488 -labelled WGA at the plasma membrane. LPA treatment had limited effects on *β-Arrestin1-*mCherry plasma membrane recruitment in Sh*PTEN* cells that have residual low level PTEN but was ineffective in *PTEN* ^-/-^ cells. We cannot attribute these findings to nonspecific fluorophore diffusion, since mCherry distribution was unaffected by PTEN status or LPA treatment. Furthermore, we can exclude PTEN nonspecific effects on cell membrane protein localization because 1,25(OH)~2~D~3-~induced plasma membrane recruitment of E-Cadherin ([@bib61]) was equivalent in PTEN-expressing and -deficient cells. Collectively, these findings show that PTEN is an essential coregulator of plasma membrane recruitment of β-Arrestin1 and of β-Arrestin1:ARHGAP21 functional interactions.

β-Arrestin1 and ARHGAP21 coregulate GTPases ([@bib2]) that function as a signaling hub for diverse cytokinetic processes ([@bib25]; [@bib30]). We investigated PTEN regulation of GTPase activity through β-Arrestin1-ARHGAP21 scaffolding and conducted perturbation experiments in organotypic 3D culture models that are ideal for precise, image-based assays of multiscale epithelial homeostasis. We found that siRNA knockdown (KD) of β-Arrestin1 suppressed Cdc42 activation in PTEN-expressing cells and 3D cultures while siRNA *ARHGAP21* KD had reciprocal effects by increasing Cdc42 activity in PTEN-deficient cultures. Furthermore, these perturbation experiments affected sequential layers of homeostatic controls. Suppression of β-Arrestin1 induced mitotic spindle misorientation, abnormal epithelial configuration, defective apical membrane positioning and formation of multiple lumens during assembly of PTEN-expressing 3D Caco-2 glandular structures. Conversely, * ARHGAP21* KD increased Cdc42 activation, restored spindle orientation and rescued aberrant morphogenesis of isogenic PTEN-deficient 3D Sh*PTEN* cultures. Because of the previously reported relationship between ARHGAP21 and RhoA ([@bib42]), we assessed relationships between PTEN, β-Arrestin1, ARHGAP21 and RhoA. PTEN KD suppressed β-Arrestin1, enhanced ARHGAP21 and suppressed RhoA activation. Collectively, these findings indicate that PTEN orchestrates the cell division plane and apical membrane dynamics during multicellular morphogenesis by coordination of β-Arrestin1-ARHGAP21 functional interactions and GTPase activity.

In accord with the above findings, we found that PTEN enhanced β-Arrestin1-ARHGAP21 interactions. PTEN interacts with β-Arrestin1 ([@bib42]), localizes to the plasma membrane ([@bib39]) and modulates multicellular morphogenesis ([@bib32]) via its C2 domain. Conversely, *PTEN* C2 domain mutations perturb multicellular patterning during development and neoplastic progression ([@bib10]) by unclear mechanisms. C2 domain molecular interactions are masked by a closed PTEN intramolecular conformation ([@bib65]). However, studies of the isolated C2 domain or an unmasked C2 mediated by alanine substitution at T383 \[T383A\] ([@bib63]) within a *PTEN* C124S mutant construct, enables study of PTEN*-*phosphatase independent C2 domain molecular interactions. A C124S A4 mutant containing alanine substitutions at Ser^380^, Thr^382^, Thr^383^ and Ser^385^ suppresses β-Arrestin1 binding ([@bib42]). We used these constructs together with appropriate tools for detection of protein binding or conformational change to investigate scaffolding functions. We found in CoIP studies that the isolated PTEN C2 domain enhanced β-Arrestin1-associated ARHGAP21 expression in excess of that induced by the C2-MCBR3 membrane-binding mutant. Bioluminescence energy transfer (BRET) analysis of Rluc-PTEN-YFP biosensor constructs containing *PTEN* CS-T383A or *PTEN*-CS-A4 (35) revealed different conformational dynamics consistent with differential protein binding. Proximity ligation assay (PLA) is a sensitive method for visualization of signals generated by protein-protein interactions ([@bib76]). We found strong interactions between unmasked or isolated PTEN C2 domains and β-Arrestin1, in excess of that observed with the C2-MCBR3 or C124S A4 mutants. Furthermore, expression of wt PTEN or the C2 domain in *PTEN *^-/-^ HCT116 cells enhanced β-Arrestin1-ARHGAP21 interaction signals, in excess of *PTEN*-MCBR3 (full-length *PTEN* mutated at the CBR3-membrane-binding loop) or C2-MCBR3. Interestingly, the *PTEN*-MCBR3 mutant had some limited scaffolding function, indicated by increased β-Arrestin1-ARHGAP21 binding in excess of control or C2-MCBR3 in PLA assays. Notwithstanding this finding, our data indicate that PTEN binds β-Arrestin1 and promotes β-Arrestin1-ARHGAP21 interactions predominantly through its intact C2 domain.

C2 domains are phospholipid and protein binding modules involved in membrane recruitment and localization of signaling molecules ([@bib12]). Here, we show that PTEN C2 enhances β-Arrestin1 expression. While precise mechanisms remain unclear, PTEN C2 binds thioredoxin-1 ([@bib51]) that regulates β-Arrestin1 in a context-dependent manner ([@bib33]). In this study, PTEN C2 also promoted membrane enrichment of β-Arrestin1 in excess of total lysate concentrations and enhanced β-Arrestin1-ARHGAP21 interactions. Interestingly, wt PTEN promoted greater β-Arrestin1-associated ARHGAP21 expression in membrane fractions than the isolated C2 domain. Within its N-terminal domain, full-length PTEN contains a conserved polybasic phosphatidylinositol\[~4,5~\] biphosphate (PtdIns \[~4,5~P~2~\]) \[PIP~2~\]-binding site that participates in membrane-targeting ([@bib81]) and could complement PTEN C2 domain-mediated interactions between scaffold complexes and membrane lipids. Similarly, in CoIP assays *PTEN*-MCBR3 promoted a small but significant increase of β-Arrestin1-associated ARHGAP21 expression in excess of C2-MCBR3. Taken together, our findings indicate that PTEN promotes β-Arrestin1-ARHGAP21 interactions predominantly through its C2 domain, although the PTEN N-terminal domain has a weak additional effect.

PTEN, β-Arrestins and GTPase-activating proteins modulate the activity of Rho GTPases CdcC42 and RhoA ([@bib49]; [@bib2]; [@bib6]; [@bib1]). Furthermore, the PTEN C2 domain has morphogenic properties ([@bib40]; [@bib32]; [@bib10]). We investigated PTEN orchestration of multicellular gland assembly through its C2 domain, in organotypic culture studies. We found greater β-Arrestin1 and lower ARHGAP21 immunoreactivity in control Caco-2 vs Sh*PTEN* 3D cultures in accord with our findings in cell monolayers. Transfection of Sh*PTEN* cells with a C2 domain construct promoted β-Arrestin1 membrane localization, rescued mitotic spindle orientation, single central lumen formation and 3D multicellular morphogenesis. Conversely, expression of the membrane-binding mutant C2-MCBR3 domain did not rescue the morphology phenotype. Sh*PTEN* cells stably express *PTEN* ShRNA that targets the phosphatase domain ([@bib31]). To assess *PTEN* ShRNA specificity and test for potential off-target effects, we investigated effects of full-length ShRNA-resistant *PTEN* (ShR *PTEN*) on the integrated Sh*PTEN* 3D morphology phenotype. Expression of ShR *PTEN* rescued 3D Sh*PTEN* morphogenesis and thus confirmed shRNA functional specificity. Collectively, the above data show that *PTEN* has important noncatalytic morphogenic functions mediated through its C2 domain and β-Arrestin1 membrane targeting.

To investigate Cdc42 activation by the unmasked *PTEN* C2 domain, we conducted expression studies in *PTEN* ^-/-^ cells. Transfection of *PTEN* CS-T383A robustly enhanced Cdc42-GTP, while the β-Arrestin1-binding defective CS-A4 mutant ([@bib42]) had no effect. Subsequent to these Cdc42 activation studies, we investigated the specific role of β-Arrestin1-ARHGAP21 interactions on Cdc42-dependent multicellular morphogenesis. We used a cell-permeant peptide analogue of the β-Arrestin1 docking site within the ARHGAP21 GAP domain (pep24) to disrupt β-Arrestin-ARHGAP21 interactions ([@bib2]). Pep24 treatment suppressed β-Arrestin1-associated ARHGAP21 expression, inhibited Cdc42 activation, induced spindle misalignment and aberrant morphogenesis of 3D Caco-2 cultures. These morphogenic effects phenocopied those of Cdc42 knockdown ([@bib31]; [@bib30]). Collectively, our findings indicate that PTEN C2 coordinates β-Arrestin1-ARHGAP21 and Cdc42-dependent multicellular morphogenesis in a 3D colorectal cancer model system.

PTEN is frequently downregulated in human colorectal ([@bib56]) and other cancers, even in the absence of genetic loss or mutation ([@bib68]). Regulatory cues may have a central role in tumorigenesis ([@bib74]). Activated GPCRs modulate β-Arrestin1 conformation ([@bib71]), membrane recruitment ([@bib80]; [@bib41]; [@bib16]) and PTEN-β-Arrestin1 interactions ([@bib42]). By these processes, GPCRs may influence β-Arrestin1-dependent GTPase activation, cytoskeletal dynamics and neoplastic multicellular patterning. Studies in cancer cell models provide useful mechanistic data ([@bib26]) but intrinsic mutations may compromise physiological relevance. Studies of 3D multicellular organoids isolated from normal tissues have provided basic insights into normal tissue morphogenesis ([@bib11]). We have previously generated intestinal crypt organoids for study of multicellular assembly, patterning and lineage commitment ([@bib7]; [@bib77]; [@bib72]). Suppression of β-Arrestin1-ARHGAP21 binding in organoid systems by pep24 treatment perturbed spindle orientation and apical membrane alignment to induce a multilumen phenotype, surrounded by disorganized epithelium. Collectively, these findings demonstrate the importance of β-Arrestin1-ARHGAP21 interactions in control of normal colorectal multicellular architecture.

Within the PTEN C2 domain, the CBR3 loop can localize cytoplasmic PTEN to early endosomes arranged along the microtubule cytoskeleton, by binding endosomal PIP~3~ ([@bib55]). Restriction of PTEN to a punctate vesicular distribution along microtubules may enable dephosphorylation of PIP~3~ signals generated by plasma membrane receptor tyrosine kinases and parcelled in endosomes ([@bib55]). However, it is difficult to envisage that wide endosomal distribution of scaffolding interactions along the microtubule cytoskeleton could regulate the compartmentalized focus of GTPase activity ([@bib62]) required for control of spindle dynamics and multicellular morphogenesis ([@bib19]). Hence, dephosphorylation of PIP~3~ on endosomes and scaffolding of β-Arrestin1-ARHGAP21 may represent spatiotemporally distinct PTEN tumor suppressor functions.

This study shows that β-Arrestin1-ARHGAP21 interactions represent an essential component of the PTEN morphogenic pathway and sheds light on conserved developmental mechanisms. In *C. elegans*, PTEN/DAF18 conducts nutrient-sensing through its phosphatase domain ([@bib59]) in a negative feedback loop with the insulin/IGF axis ([@bib57]) and casein kinase II \[CKII\] ([@bib44]). CKII phosphorylates PTEN to induce the closed conformation ([@bib65]; [@bib78]) that suppresses plasma membrane binding ([@bib65]). We show that the PTEN membrane-binding C2 domain is essential for multicellular morphogenesis. Hence, our findings may provide a rationale for PTEN multifaceted control of embryonic development by nutrient-sensing ([@bib59]) and regulation of morphogenic growth ([@bib67]) according to the available nutrient energy balance ([@bib28]). Our study also has oncological relevance, since disruption of PTEN C2 domain-mediated β-Arrestin1-ARHGAP21 interactions drive evolution of morphology phenotypes in 3D cultures that are evocative of colorectal cancer ([@bib15]; [@bib30]). Dissection of these phenomena may yield novel targets for therapy aimed at suppression of aggressive cancer morphology phenotypes that predict early metastasis.

Materials and methods {#s4}
=====================

Reagents and antibodies {#s4-1}
-----------------------

All laboratory chemicals were purchased from Sigma-Aldrich, Dorset, England unless otherwise stated. RNAiMAX and X-tremeGENE transfection reagents were purchased from Thermofisher, Dublin, Ireland and Roche, Basel, Switzerland, respectively. Antibodies used in this study were anti-β-Actin (A5316; Sigma Aldrich, Dorset, England \[RRID:[AB_476743](https://scicrunch.org/resolver/AB_476743)\]); anti-β-Arrestin1 (ab32099; Abcam, Cambridge, UK \[RRID:[AB_722896](https://scicrunch.org/resolver/AB_722896)\]); anti-ARHGAP21 (55139-1-AP; Proteintech Manchester, UK \[RRID:[AB_10794449](https://scicrunch.org/resolver/AB_10794449)\]); anti-E-Cadherin (562526; BD Biosciences, Oxford, UK \[RRID:[AB_11153868](https://scicrunch.org/resolver/AB_11153868)\]); anti-GAPDH (ab8245; Abcam, Cambridge, UK \[RRID:[AB_2107448](https://scicrunch.org/resolver/AB_2107448)\]); anti-GFP (ab8245; Abcam, Cambridge, UK \[RRID:[AB_298911](https://scicrunch.org/resolver/AB_298911) \]); anti-HSP90 (sc-7947; Santa Cruz, Dallas, Texas, USA \[RRID:[AB_2121235](https://scicrunch.org/resolver/AB_2121235)\]); anti-Pericentrin (PCN:ab4448; Abcam, Cambridge, UK \[RRID:[AB_304461](https://scicrunch.org/resolver/AB_304461)\]); anti-Protein Kinase C ζ \[PRKCZ\] (ab51157; Abcam, Cambridge, UK \[RRID:[AB_882057](https://scicrunch.org/resolver/AB_882057)\]); anti-PTEN (ab32199; Abcam, Cambridge, UK \[RRID:[AB_777535](https://scicrunch.org/resolver/AB_777535)\]); anti-α-Tubulin (Ab7291; Abcam, Cambridge, UK \[RRID:[AB_2241126](https://scicrunch.org/resolver/AB_2241126)\]); anti-Cdc42 (ab41429; Abcam, Cambridge, UK \[RRID_726768\]) and anti-Cdc42-GTP (26905; New East Biosciences, PA, USA, \[RRID:[AB_1961759](https://scicrunch.org/resolver/AB_1961759)\]). These primary antibodies were used where appropriate in conjunction with Li-Cor IRDye 680 (anti-rabbit) \[RRID:[AB_621841](https://scicrunch.org/resolver/AB_621841)\] and IRDye 800 (anti-mouse) \[RRID:[AB_10793856](https://scicrunch.org/resolver/AB_10793856)\] secondary antibodies, for use with the Li-Cor Infra-Red imaging systems (Li-Cor Biosciences, Lincoln, Nebraska, USA) in Western blots or with Alexa Fluor 568 (anti-rabbit) \[RRID:[AB_143011](https://scicrunch.org/resolver/AB_143011)\] and Alexa Fluor 488 (anti-mouse) \[RRID:[AB_141626](https://scicrunch.org/resolver/AB_141626);Molecular probes, Invitrogen, CA, USA\] and/or anti-mouse CY5 (Jackson Immunoresearch, Newmarket, Suffolk, UK\[RRID:AB\_\[RRID:[AB_2340152](https://scicrunch.org/resolver/AB_2340152)\]) for fluorescence or confocal microscopy. We obtained Alexa 488-labeled wheat germ agglutinin (WGA) from ThermoScientific Dublin (Product No W11261). DNA was imaged with DAPI (Vector Scientific, Belfast, NI) while FITC-labeled phalloidin (p5282; Sigma-Aldrich, Dorset, England) was used to image apical actin in organoid cultures. For PLA, studies we used mouse anti-*β-Arrestin1* from ThermoScientific, Paisley, UK with Duolink in situ fluorescence kits, (Sigma-Aldrich, Dorset, England) according to manufacturer's instructions. SiRNA oligonucleotides targeted against *β-Arrestin1* (Qiagen Flexitube; 1027417) or *ARHGAP21* (Dharmacon SmartPool; L-009382-01-0005) or nontargeting (NT) scrambled controls were purchased from Fisher Scientific, Dublin, Ireland. The cell permeant β-Arrestin1-ARHGAP21 binding disruptor peptide \[pep24 - based on amino acids 1331 to 1355 within the ARHGAP21 GAP domain ([@bib2])\] and scrambled control peptide were purchased from *EZ* Biolabs, Carmel, IN 46032 USA. Pep24 and control peptides were prepared in dimethyl sulfoxide (DMSO), according to manufacturer's instructions. For the pep24 experiments, cells were incubated in 2D or 3D cultures as outlined below for 48 hr, then treated with either 10 μM pep24 or 10 μM control peptide. Incubations were continued for 24 hr for assays of protein binding or Western blots in cell monolayers. In 3D morphogenesis assays, test and control peptides were added to the media in the above concentrations, changed at 48 hr intervals and effects on morphogenesis assessed at 4 days of culture.

Cell lines {#s4-2}
----------

Stable *PTEN*-deficient Caco-2 Sh*PTEN* (Sh*PTEN*) cells were generated by transfection of parental Caco-2 cells (obtained from the American Type Culture Collection, Manassas, VA \[RRID:[CVCL_0025](https://scicrunch.org/resolver/CVCL_0025)\]) with replication-defective retroviral vectors encoding *PTEN* short hairpin RNA (ShRNA), using the Phoenix retroviral expression system (Orbigen, San Diego, CA USA), as previously described ([@bib31]; [@bib14]). *PTEN ^+/+^* HCT116 \[RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)\] and *PTEN ^-/-^* HCT116 (here known as HCT116 and *PTEN ^-/-^*) colorectal epithelial cells were a gift from Dr Tod Waldman, Georgetown ([@bib38]) and were cultured in McCoys 5A media supplemented with 10% FCS (fetal calf serum), 1 mM L-glutamine and 1 mM sodium pyruvate. Caco-2 and Sh*PTEN* cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented 10% FCS, 1 mM non-essential Amino Acids and 1 mM L-Glutamine at 37°C in 5% CO~2~. In 3D cultures, Caco-2, Sh*PTEN* cells and subclones transfected with SiRNAs, *PTEN* C2 domain or empty vector (EV) control constructs, were cultured embedded in a Matrigel matrix (BD Biosciences, Oxford, UK), as previously described ([@bib31]; [@bib32]). Caco-2 and HCT116 cells were characterized in terms of *PTEN* expression, AKT signaling, GTPase activation ([@bib31]) and Caco-2 morphogenic growth ([@bib31]). Furthermore, short tandem repeat (STR) profiling ([@bib9]) conducted by LGC Standards, Middlesex, UK confirmed authenticity by 100% and 94% matches, respectively, between study parental Caco-2 and HCT116 cells and original American Type Culture Collection (ATCC) derivatives.

Cell transfection {#s4-3}
-----------------

We carried out mammalian SiRNA and DNA transfections using RNAiMAX and X-tremeGENE transfection reagents respectively, according to manufacturer's protocols. Cells were plated at 2 × 10^5^ cells/35 mm dish for 24 hr, then transfected with 10 µM siRNA or 500 ng DNA/2 × 10^5^ cells for all respective siRNA oligonucleotides or DNA constructs. Cells were incubated with RNA/RNAiMAX or DNA/X-tremeGENE lipofectamine complexes for 48 hr, before lysis and probing. In 2 Sh*PTEN* cells, the stably expressed *PTEN* ShRNA targets a 58 base pair region within the *PTEN* phosphatase coding region and C2 domain constructs are unaffected ([@bib4]). In membrane localization studies, PTEN-expressing and -deficient Caco-2 and HCT116 clones were transfected with β-Arrestin1-mCherry against mCherry only controls. In expression, co-immunoprecipitation and morphogenesis studies, Sh*PTEN* cells were transiently transfected with empty vector (EV) only, the isolated *PTEN* C2 domain (C2) or a C2 domain construct mutated at the CBR3 membrane-binding loop \[C2-MCBR3\] ([@bib39]) in pEGFP expression vectors.

*PTEN* mutants {#s4-4}
--------------

*PTEN*-C124S-A4 and *PTEN*-C124S-T383A were generated by introduction of four alanine substitutions at Ser380, Thr382, Thr383 and Ser385 and by alanine substitution at Thr383 only, respectively ([@bib63]) into lipid and protein phosphatase dead *PTEN* C124S ([@bib48]). These mutants suppress or enhance β-Arrestin1 binding, respectively ([@bib42]). *PTEN*-MCBR3, the isolated C2 domain and C2-MCBR3 were gifts from Dr N Leslie, Dundee and were generated by replacement of 263-K-M-L-K-K-D-K-269 in the C2 domain CBR3 membrane targeting loop with the 263-A-A-G-A-A-D-A-269 sequence ([@bib39]), as previously described ([@bib32]). Sequence specificities of C2-MCBR3 and *PTEN*-MCBR3 mutants were confirmed by sequencing studies.

Cell fractionation {#s4-5}
------------------

We conducted these experiments using a subcellular fractionation kit (Thermo Fisher Scientific, Dublin, Ireland) according to manufacturer's protocol. Briefly, cells were trypsinized and lysed in cytoplasmic extraction buffer for 10 min at 4°C, then centrifuged at 500 g for 5 min. The supernatant was collected as the cytoplasmic fraction while the pellet was resuspended in membrane extraction buffer, vortexed for 5 s and mixed gently for 10 min at 4°C. The mix was centrifuged at 3000 g for 5 min and the supernatant was collected as the membrane fraction. In separate experiments, we conducted protein extraction, Western blotting and co-immunoprecipitation (Co-IP) assays in isolated cell membrane and cytosolic fractions. Equivalent amounts of membrane fraction and cytosol were loaded in immunoblots and Co-Ips.

Protein extraction and western blotting {#s4-6}
---------------------------------------

As previously described ([@bib31]; [@bib32]), proteins were resolved using gel electrophoresis, followed by blotting onto nitrocellulose membranes. Membranes were probed using antibodies as indicated in the text. Experiments were repeated in triplicate.

Co-immunoprecipitation (Co-IP) {#s4-7}
------------------------------

Cells were lysed on ice in buffer containing 100 mM Tris-HCl, pH 7.5, 1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 50 mM NaCl, 5 mM NaF, 1 mM Na~3~VO~4~ and protease inhibitor. Cell lysates were centrifuged (for 10 mins at 15,000 g) and protein concentrations were measured by the BCA method. 1000 µg of protein was precleared overnight with control IgG and 15 μl of Protein A/G Sepharose beads (Santa Cruz, Dallas, Texas, USA). The protein was then immunoprecipitated with the appropriate antibody-beads conjugate and incubated on a rotating wheel for 2 hr. The beads were collected by centrifugation and washed five times in wash buffer (50 mM Hepes, pH 7.4, 1% Triton X-100, 0.1%, SDS, 150 mM NaCl, 1 mM Na~3~VO~4~). The beads were subsequently resuspended in 40 µl Laemmli sample buffer and processed for gel electrophoresis.

GST-based-GTPase pulldown assays {#s4-8}
--------------------------------

Experiments were conducted as previously described ([@bib15]; [@bib32];). Briefly, cells were grown on 90 mm dishes then lysed in buffer comprising 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 100 mM NaCl, 10 mM MgCl~2~, 5% glycerol, 1 mM Na~3~VO~4~ and protease inhibitor cocktail (Roche) and centrifuged at 12,500 g for 10 min. We assayed the GTP-bound form of RhoA by adding GST-Rhotekin fusion protein coupled with gluthathione sepharose 4B beads (Sigma-Aldrich, Dorset, England) to 1 mg of cell lysate. Beads were collected after 1 hr by centrifugation, washed x3 and resuspended in Laemmli buffer with 1 mM DTT. RhoA -GTP levels were then assayed by western blotting. Experiments were repeated in triplicate.

Proximity ligation assays {#s4-9}
-------------------------

We assessed protein-protein proximities using the Duolink II red kit (Sigma-Aldrich, Dorset, UK) according to the manufacturer's instructions. Briefly, we transfected *PTEN*^-/-^ cells with GFP tagged-EV or -*PTEN* constructs and cultured the cells in Millipore eight well chambers. After 24 hr, we fixed the cells with 4% paraformaldehyde (PFA) at room temperature for 20 min. We then permeabilized the cells with 0.05% TritonX100 in PBS for 10 min. Cells were blocked with immunofluorescence (IF) buffer (Duolink, Sigma-Aldrich, Dorset), England for 2 hr according to manufacturer's instructions and incubated with primary antibody overnight at 4°C. Cells were washed twice with buffer A, and incubated with PLA probe, ligase and polymerase according to the manufacturer's protocol. Finally, cells were washed with buffer B and slides were mounted with a cover slip using Duolink in situ mounting medium with DAPI.

BRET assays {#s4-10}
-----------

BRET investigations were performed as described previously ([@bib43]). Briefly, HEK cells were transfected with the indicated plasmids 24 hr after seeding. At 24 hr post transfection, cells were detached, resuspended in full media, and distributed into poly-l-orthinine coated white 96-well optiplates (Perkin Elmer). The following day, cells were washed with PBS and then overlayed with HBSS. Coelenterazine h was added to a final concentration of 5 mM and incubated for 3 min at 25°C. BRET readings were collected using a Multimode Reader Mithras^2^ LB 943 (Berthold Technologies). Substrate and light emissions were detected at 480 nm (Rluc) and 540 nm (YFP) for 1 s. The BRET signal was calculated by ratio of the light emitted by YFP and the light emitted by Rluc (YFP/Rluc). The ratio values were corrected by substracting background BRET signals detected when Rluc-*PTEN* was expressed. mBRET values were calculated by multiplying these ratios by 1000. ∆mBRET values are shown to demonstrate the shift in BRET signal compared to wt signal, which is set to zero, or between the two mutants (C124S-T383A and C124S-A4) that were tested.

Three-dimensional (3D) cultures and morphogenesis assays {#s4-11}
--------------------------------------------------------

Caco-2 and Caco-2 Sh*PTEN* cells were cultured and embedded in Matrigel matrix (BD Biosciences, Oxford, UK), then imaged by confocal microscopy as we previously described ([@bib31]; [@bib32]). Briefly, 6 × 10^4^ trypsinized cells were mixed with Hepes buffer (20 mM, pH 7.4) and Matrigel (40%) in a final volume of 100 μl, placed in each well of eight-well multichambers (BD Falcon, Fisher Scientific, Dublin, Ireland), allowed to solidify for 30 min at 37°C and subsequently overlayed with 400 μl of media/well. We imaged the 3D cultures at progressive stages of morphogenesis as previously described ([@bib31]; [@bib32]).

Colorectal organoid cultures {#s4-12}
----------------------------

We used C57B/6 wild-type mice (1--6 weeks old) for experiments and conducted all animal procedures in accordance with local and national regulations. We isolated organoids as previously described ([@bib77]; [@bib72]). Briefly, murine colons were opened longitudinally, cut into 0.5 cm fragments, washed 7--10 times in 1x HBSS (low calcium, low magnesium (Gibco-BRL), 2% D-glucose, 0.035% NaHCO~3~) to remove all luminal contents. The fragments were then finely chopped with a scalpel and digested in HBSS solution containing collagenase and dispase I neutral proteases (Sigma-Aldrich, Dorset, UK) at 1 mg/ml for 20 min at room temperature on a shaking platform. Digestion was stopped by the addition of 30 ml DMEM/F12 culture medium (Life Technologies, Renfrew UK) supplemented with 5% FCS containing penicillin and streptomycin. Large fragments and muscle sheets were allowed to settle to the bottom of the flask. We removed the supernatant containing the organoids and centrifuged it for 3 min at 250 rpm, to pellet the organoids. We removed the supernatant and gently resuspended the organoid pellet in 20 ml of the DMEM/F12 solution. We repeated the centrifugation step 5--6 times until the pellet contained a homogeneously sized organoid preparation. Organoids thus prepared were resuspended in a 2x volume of Matrigel (growth factor reduced, phenol red free; BD Biosciences, Oxford UK) supplemented with 50 ng/ml murine EGF, murine Noggin 100 ng/ml (PeproTech, NJ, USA) and 1 μg/ml human R-Spondin, as indicated for organoid culture ([@bib70]). Eight well multichambers were coated with a thin layer of undiluted Matrigel and allowed to solidify. Organoid preparations in Matrigel (100 μl suspension) were placed into each well, then overlaid with 250 μL/well culture medium (Dulbecco\'s modified Eagle medium/F12) supplemented with penicillin/streptomycin, 10 mmol/L HEPES, Glutamax supplements 1× N2, 1 × B27 \[Invitrogen\], 1 mmol/L *N*-acetylcysteine \[Sigma\]), 50 ng/ml murine EGF, Noggin 100 ng/ml and 1 μg/ml human R-Spondin ([@bib70]). We cultured the organoids for 4 days with peptide treatments as defined.

Confocal immunofluorescence microscopy {#s4-13}
--------------------------------------

Membrane and cytosolic localization of β-Arrestin1*-*mCherry or mCherry only were imaged against Alexa 488-labelled WGA, a widely used fluorescent marker that binds to cell membranes ([@bib13]) in Caco-2, Sh*PTEN,* HCT116 and *PTEN* **^−/−^** cells, with or without LPA treatment. We used a Leica SP8 confocal microscope and Leica LAS-X software for line scanning of fluorescent images. Caco-2 Sh*PTEN* (Sh*PTEN*) glands and organoid cultures were incubated in 4% PFA for 20 min and processed for immunofluorescence as previously described ([@bib31]; [@bib15]; [@bib32]). Briefly, 3D cultures were fixed in PFA for 20 min at room temperature and permeabilized for 10 min in 0.5% Triton X-100 in PBS. The 3D cultures were rinsed with PBS/glycine buffer for 15 min to reduce autofluorescence and blocked by incubation in IF Buffer (PBS with 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20)+10% goat serum, for 1--1.5 hr at room temperature. Primary antibodies were diluted in blocking buffer and incubated overnight at 4^°^C. The 3D cultures were incubated with secondary antibodies and/or FITC-labeled phalloidin for 1 hr. DNA was stained using Vectashield mounting medium containing DAPI (Vector Scientific, Belfast, NI). Sequential scan images were taken the midsection of glands/organoids at room temperature using a Leica SP5 confocal microscope \[RRID:[SCR_012314](https://scicrunch.org/resolver/SCR_012314)\] on a HCX PL APO lambda blue 63 × 1.40 oil immersion objective at 1x or 2x zoom. Images were collected and scale bars added using LAS AF confocal software (Leica) \[RRID:[SCR_013673](https://scicrunch.org/resolver/SCR_013673)\]. We assessed effects of transfection or treatment on signal intensity, spindle orientation, lumen formation and/or epithelial configuration in in 3D glands or organoids at 4 days of culture. Because imaging for apical protein kinase C zeta (PRKCZ) was unsuccessful in organoids, the apical domain was imaged using FITC-labelled phalloidin as a marker of apical actin.

Assessment of mitotic spindle orientation {#s4-14}
-----------------------------------------

In cultured cells, centrosomes (Csms) were identified using anti-pericentrin (PCN) and microtubules by anti-α-Tubulin antibodies, respectively, and we identified chromosomal DNA by DAPI staining. We defined bipolar mitotic spindle architecture by convergence of microtubules towards each of 2 spindle poles, as we previously described ([@bib15]). Caco-2 and Caco-2 sh*PTEN* glands were cultured in Matrigel for 4 days, fixed with 4% PFA and stained with anti α-Tubulin, PRKCZ and PCN primary antibodies. Gland midsections were imaged by confocal microscopy to identify cells containing well-formed mitotic spindles, during metaphase or anaphase. Lines connecting each spindle extremity were drawn using ImageJ and the line center was considered as the spindle midpoint. Angles between spindle planes and lines connecting spindle midpoints to gland centres were measured, as outlined previously ([@bib15]; [@bib30]). We used a similar approach or imaging of organoid morphogenesis and identified apical domains and spindles using FITC-labeled phalloidin and anti-α-Tubulin antibodies, respectively.

Image processing and statistical analysis {#s4-15}
-----------------------------------------

Confocal microscopy images were processed using Leica Fw4000 Imaging software and cropped using Adobe Ilustrator \[RRID:[SCR_014198](https://scicrunch.org/resolver/SCR_014198)\]. Confocal images were processed, merged and mean area quantified using LAS AF Leica imaging software, as previously described ([@bib31]; [@bib32]). We assessed lumen formation, spindle orientation and signal intensities using 50, 15 or 10 × 3D Caco-2 or Sh*PTEN* glandular cultures (glands) in triplicate for each experimental condition, respectively. We selected glands with mitotic figures for spindle orientation assays. Organoids were fewer in number and we assessed lumen formation and spindle orientation in 10 organoids per experimental condition, in triplicate. Multicellular structures with single central lumens were expressed as a percentage and spindle orientation angles relative to gland centres were calculated using ImageJ.

Data analysis {#s4-16}
-------------

Descriptive statistics were expressed as the mean ± sem. Statistical analyses were by one or two-way ANOVA with the Tukey post hoc test or Student's paired t test using Graphpad Prism software (v5; Graphpad CA 92037 USA \[RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)\]). Scatterplots and bar charts were used for display of quantitative numerical or categorical data.
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\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"PTEN controls glandular morphogenesis through a juxtamembrane β-Arrestin1/ARHGAP10 scaffolding complex\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by Mohan Balasubramanian as Reviewing Editor and a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Michel Bagnat (Reviewer \#4).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The reviewers and the editors found the premise of your study, of a non-catalytic function of PTEN in morphogenesis via modulation of β-arrestin dynamics very interesting. While the reviewers were positive about your study, in discussions it emerged that all of them agreed that the biochemical experiments raised important concerns.

In light of this, we urge you and your colleagues to carefully address the concerns raised, by all four reviewers. In particular, reviewer 1 has detailed the concerns in all the 7 points this reviewer has raised. Some of these points have raised by each of the other three reviewers.

Our decision is to turn down the submission, as we do not know if your current conclusions will stand after the experiments we suggest are completed. If the conclusions still hold up, we will be happy to review a new manuscript from you, should you wish to submit to *eLife*.

Reviewer \#1:

In this paper, Javadi et al. describe their investigation of the function of the tumor suppressor PTEN in morphogenesis and spindle orientation in 3D multicellular organoids. They concluded that the loss of PTEN or β arrestin causes impairment in both these functions and that these defects are restored by activation of Cdc42 through suppressing its GTPase activation protein, ARHGAP10. They also suggest that PTEN controls the interaction between β arrestin and ARHGAP10 through its C2 domain, and that disruption of this interaction leads to the inhibition of Cdc42. The data for the 3D organoid formation and the regulation for spindle orientation are very interesting and convincing. However, this reviewer has several problems with the presentation and reproducibility of the data, which makes scientific interpretation difficult. I believe the authors should meticulously review their manuscript and remedy the problems in this otherwise potentially very interesting and important work. Specifically:

1\) In [Figure 1](#fig1){ref-type="fig"}, the authors show that knockout or knockdown of PTEN leads to decreased membrane-bound β arrestin levels and increased membrane-bound ARHGAP10 levels, as evidenced by a crude membrane fractionation assay. However, the amounts of membrane-bound β arrestin are inconsistent between [Figures 1A and B](#fig1){ref-type="fig"} (showing a 50% decrease) and [Figures 1E and F](#fig1){ref-type="fig"} (showing almost no decrease). To compare each group shown in [Figure 1F](#fig1){ref-type="fig"}, statistical analysis was performed only by ANOVA without multiple comparisons. Furthermore, for the same experiment shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, Western blotting does not show a decrease in membrane-bound β arrestin levels in PTEN KO, although the quantification shows a 20% decrease at the basal level (before LPA stimulation). Again, statistical analysis is incomplete.

2\) The intracellular localization of β arrestin is shown in [Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. The images are improperly modified; the size and cropped area are not the same in each image. Also, in each case, the image quality is very low and pixelated, making it difficult to evaluate their plasma membrane localization.

3\) In [Figure 1A](#fig1){ref-type="fig"}, the authors suggest that in the PTEN knockdown, the β arrestin level in the membrane fraction decreases while the ARHGAP10 level increases. They also show in [Figure 4](#fig4){ref-type="fig"} that expression of the C2 domain of PTEN restores these changes caused by PTEN KD/KO. There is no ARHGAP10 in the cytosol fraction. The authors should include essential control to show that the total amounts of β arrestin and ARHGAP10 are not affected by PTEN KD/KO. What percentage of cytosolic and membrane proteins are loaded?

4\) In a related note, the loss of PTEN may simply change the expression levels of β arrestin and ARHGAP10 and not their membrane localizations. This possibility is supported by many data (intensity of β arrestin in [Figure 1C](#fig1){ref-type="fig"}, Western data for total β arrestin expression in cells expressing C2 in [Figure 3D](#fig3){ref-type="fig"}, and increased intensity of β arrestin and decreased intensity of ARHGAP10 in C2-expressing 3D organoids in [Figure 5A-D](#fig5){ref-type="fig"}).

5\) In [Figure 3](#fig3){ref-type="fig"}, the authors show that loss of PTEN decreases β arrestin-ARHGAP10 interaction. Ectopic expression of the C2 domain, but not the MCBR3 mutant, rescues this phenotype. The expression levels of C2 and MCBR3 should be examined to exclude the possibility that they have different expression levels and that is the reason for their distinct rescuing activities. They should also test whether C2 or MCBR3 interacts with the β arrestin-ARHGAP10 complex.

6\) In [Figures 4A](#fig4){ref-type="fig"} through F, the authors show that expression of C2 leads to increases in the amounts of membrane-bound β arrestin and decreases in membrane-bound ARHGAP10 levels in PTEN KD/KO cells. How much C2 and MCBR3 are associated with the membrane fraction? Again, the authors need to show the total expression levels of these proteins.

7\) The increase in β arrestin in the membrane fraction by the expression of C2 shown in [Figure 4D](#fig4){ref-type="fig"} is not observed in [Figures 4G](#fig4){ref-type="fig"} and I.

Reviewer \#2:

Previous studies have shown that b-arrestin interacts with ARHGAP10 and negatively regulates its GAP activity. Here the authors show that PTEN positively regulates membrane localization of b-arrestin. Consistent with previously reported findings the authors show that the C2 domain of PTEN mediates the interaction with b-arrestin. In addition, the author investigate the biological significance of this pathway using caco2 3D culture system and investigate changes in spindle orientation during cell division and its effect of morphogenesis. This is an interesting study that connects PTEN with ARHGAP10 pathways and adds more insight into the previously known relationship between PTEN and b-arrestin. However, as outlined below, additional insights into the relationship between PTEN and b-arresting/ARHGAP10 interaction would increase the impact of the study.

[Figure 1A](#fig1){ref-type="fig"} -- the authors state loss of PTEN results in \"greater b-arresting but lower ARHGAP10 levels in membrane fractions\" but the data presented show a lower b-arrestin and greater ARHGAP10.

[Figure 1C](#fig1){ref-type="fig"}: Can the authors show a control membrane protein that can translocate to membrane upon a ligand stimulation irrespective of PTEN levels. This control will rule a non-specific effect of PTEN knockdown that interferes with membrane biology.

The authors should determine changes in RHOA activity and its potential role in the morphogenesis phenotype reported here because of the previously reported relationship between ARHGAP10 and RhoA.

The authors show PTEN loss decreases b-arrestin-ARHGAP10 interaction, however it is not clear how loss of PTEN affects the interaction between b-arrestin and ARHGAP10. The authors should provide a clear insight into the mechanistic basis for this observation.

Reviewer \#3:

The manuscript \"PTEN controls glandular morphogenesis through a juxtamembrane b-arrestin1/ARHGAP10 scaffolding complex\" from Javadi et al., builds on previous molecular data demonstrating that (i) b-arr1 can interact with the C2 domain of PTEN to regulate phosphatase-independent PTEN functions, and (ii) that b-arr1 binds and suppresses the GAP ARHGAP10/21, to reveal that glandular morphogenesis is controlled through juxtamembrane b-arr1/ARHGAP10/CDC42 dynamics. The study adds new knowledge to how PTEN and b-arr1 can coordinately regulate cell polarity in multicellular architecture, and that changes in this complex drives morphological defects in relevant colorectal cancer models. While the work is well done, some critical controls are missing and some mechanistic points could be further developed and discussed to strengthen the findings.

In [Figure 1C](#fig1){ref-type="fig"} b-arr1 staining in the PTEN-deficient lines is weak. Enhanced contrast images should also be shown so the reader can more readily analyze the panels. Why is there a discrepancy between the blot data (in [Figure 1A, a](#fig1){ref-type="fig"} small effect on the b-arr1 signal) and the IF data (in [Figure 1C, a](#fig1){ref-type="fig"} large decrease in signal)? The authors also state in [Figure 5](#fig5){ref-type="fig"} that the isolated C2 domain enhanced b-arr1 immunoreactivity and decreased ARHGAP10 immunoreactivity, but do not come back to it in the discussion. Please discuss these findings further.

In [Figure 3A](#fig3){ref-type="fig"} another gel should be shown for the ARHGAP10 blot in Caco-2 shPTEN cells, as there appears to be a technical issue that would affect quantification. How many times was this experiment performed? The same goes for [Figure 4D](#fig4){ref-type="fig"}. Also, in all coIP experiments in [Figure 3](#fig3){ref-type="fig"}, control experiments should be performed with non-relevant control antibodies. Another issue, in [Figure 3D and F](#fig3){ref-type="fig"}, is that blots should be shown to demonstrate equivalent expression of C2 and C2MCBR3. The same holds for [Figures 4 A](#fig4){ref-type="fig"} and D.

What is the effect of CBR3 mutation in the FL PTEN in [Figure 4I-J](#fig4){ref-type="fig"}?

The authors use a previously characterized cell-permeant disruptor peptide to inhibit the b-arr1/ARHGAP10 complex (Anthony et al., MCB 2011). It would also be interesting to test the effect of inhibiting the b-arr1/PTEN complex, which would additionally strengthen the molecular data. One way to do this would be to use previously characterized PTEN mutants that display differential binding to b-arr1 in a phosphatase-independent setting (Lima-Fernandes et al. EMBO J 2011). In a catalytically dead context (C124S), mutation of Thr 383 to Ala increases b-arr1/PTEN binding whereas mutation of Ser380, Thr382, Thr 383 and Ser385 altogether to Ala decreases b-arr1/PTEN binding. If the authors can recapitulate this difference in binding, in their colorectal model systems, the effect of reintroducing these mutants on active Cdc42 levels and morphology phenotypes could be compared.

The discussion should be expanded to give a more comprehensive overview on GPCR/b-arr/PTEN regulation and the functional effects previously attributed to the b-arr1/ARHGAP10 (stress fibre formation) and PTEN interactions (cell proliferation and migration). It would also be good to have a schematic of PTEN showing the C2 domain and the sequence of the mutant that was generated to create MCBR3. Similarly, a schematic of ARHGAP10, with the b-arr1 binding site and sequence of disruptor peptide used would be good to have.

Reviewer \#4:

In this manuscript the authors investigate the role of the C2 domain of PTEN in controlling CDC42-dependent processes (i.e. spindle orientation and lumen formation) in Caco-2 3D cultures via regulation of β-Arrestin1/ARHGAP10 interaction. Because the PTEN C2 domain alone is sufficient to mediate the effect of PTEN the authors conclude that in this context PTEN functions as a scaffold rather than via its lipid modifying activity.

The non-catalytic function of PTEN via β-Arrestin1/ARHGAP10 is a novel an interesting result that is well supported by transfection (i.e. KD and rescue) experiments. There are however aspects of the mechanistic regulation of the proposed scaffolding function that are less convincing. Specifically, the co-IP experiments shown in [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} are not as convincing as the spindle orientation and lumen formation data. This may be due to technical limitations, co-IP/WB approaches are hardly quantitative and make detention of subtle differences difficult. It would be best if the authors could revisit their protein interaction experiments using other complementary methods such as proximity ligation, split systems or FRET.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"*PTEN* controls glandular morphogenesis through a juxtamembrane *β-Arrestin1 /ARHGAP10* scaffolding complex\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Mohan Balasubramanian) and K VijayRaghavan as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Michel Bagnat (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The editors and the reviewers agreed that your work reporting the new functions of PTEN you describe vis-a-vis interactions with β-arrestin, ARHGAP21 interesting. However, a number of further points have been raised. We would like to invite you to revise the manuscript accordingly.

I would also like you to proofread the entire manuscript and figures carefully.

Essential revisions:

Point 2. [Figure 1C](#fig1){ref-type="fig"} and supplement. The image quality is still low, perhaps because of the pdf size, but some images also appear out of focus. They are not of adequate quality to show plasma membrane localization of β-arrestin1 or any change in its localization with and without PTEN expression or LPA stimulation. The higher magnification areas and use of β-arrestin1-GFP do not help here. Inclusion of a membrane marker is essential (e.g. GFP-K-Ras C-terminus) to indicate where the plasma membrane is. Although the authors rule out quantification, it is possible to draw line scans across the cells, and determine whether or not β-arrestin1 co-localizes with the plasma membrane marker. Confocal z-stacks might help to indicate the localization better. Why are the scale bars in a different place in each image? All images should be at the same scale, and then one scale bar in one image is adequate.

10.7554/eLife.24578.089

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

*Reviewer \#1:*

> *In this paper, Javadi et al. describe their investigation of the function of the tumor suppressor PTEN in morphogenesis and spindle orientation in 3D multicellular organoids. They concluded that the loss of PTEN or β arrestin causes impairment in both these functions and that these defects are restored by activation of Cdc42 through suppressing its GTPase activation protein, ARHGAP10. They also suggest that PTEN controls the interaction between β arrestin and ARHGAP10 through its C2 domain, and that disruption of this interaction leads to the inhibition of Cdc42. The data for the 3D organoid formation and the regulation for spindle orientation are very interesting and convincing. However, this reviewer has several problems with the presentation and reproducibility of the data, which makes scientific interpretation difficult. I believe the authors should meticulously review their manuscript and remedy the problems in this otherwise potentially very interesting and important work. Specifically:*
>
> *1) In [Figure 1](#fig1){ref-type="fig"}, the authors show that knockout or knockdown of PTEN leads to decreased membrane-bound β arrestin levels and increased membrane-bound ARHGAP10 levels, as evidenced by a crude membrane fractionation assay. However, the amounts of membrane-bound β arrestin are inconsistent between [Figures 1A and B](#fig1){ref-type="fig"} (showing a 50% decrease) and [Figures 1E and F](#fig1){ref-type="fig"} (showing almost no decrease). To compare each group shown in [Figure 1F](#fig1){ref-type="fig"}, statistical analysis was performed only by ANOVA without multiple comparisons. Furthermore, for the same experiment shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, Western blotting does not show a decrease in membrane-bound β arrestin levels in PTEN KO, although the quantification shows a 20% decrease at the basal level (before LPA stimulation). Again, statistical analysis is incomplete.*

We thank the reviewer for his assessment of our manuscript and helpful criticisms. We have now repeated the membrane fractionation, immunoblot, Co-IP studies and added statistics. While we found experimental variation in absolute densitometry values, differences of juxtamembrane *β-Arrestin1* and *ARHGAP10* protein levels between *PTEN*-expressing and deficient cells are significant in the new experiments. Our findings are shown in new [Figures 1A, B, E, F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"} and new Figure 1---figure supplements 5-9. We have repeated statistical analysis of the new experimental findings and conducted ANOVA Tukey post hoc tests for [Figure 1F](#fig1){ref-type="fig"} and other figures. We show significant differences of juxtamembrane *β-Arrestin1* between *PTEN --* expressing and -- deficient cells both in basal conditions and after LPA stimulation. We have supplemented the Western blots by membrane localization studies of fluorescently tagged *β-Arrestin1* constructs ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We have also supplemented Co-IPs by more sensitive proximity ligation assays to demonstrate protein complex formation in vivo (See below).

> *2) The intracellular localization of β arrestin is shown in [Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. The images are improperly modified; the size and cropped area are not the same in each image. Also, in each case, the image quality is very low and pixelated, making it difficult to evaluate their plasma membrane localization.*

In response to this important concern, we have now conducted new intracellular localization studies for [Figure 1C](#fig1){ref-type="fig"} using a GFP-labelled *βArrestin1* construct *vs* GFP control. We have also used high power inserts to better demonstrate differences in membrane localization of *β-Arrestin1*-GFP between *PTEN*-expressing and -deficient cells, after LPA stimulation. These studies are supported by new quantitative cell fractionation and immunoblot studies that show significant membrane expression differences. These additional experiments more clearly show effects of *PTEN* on membrane localization of *β-Arrestin1*.

> *3) In [Figure 1A](#fig1){ref-type="fig"}, the authors suggest that in the PTEN knockdown, the β arrestin level in the membrane fraction decreases while the ARHGAP10 level increases. They also show in [Figure 4](#fig4){ref-type="fig"} that expression of the C2 domain of PTEN restores these changes caused by PTEN KD/KO. There is no ARHGAP10 in the cytosol fraction. The authors should include essential control to show that the total amounts of β arrestin and ARHGAP10 are not affected by PTEN KD/KO. What percentage of cytosolic and membrane proteins are loaded?*

To address these key points, we conducted expression assays of total *β-Arrestin1* and *ARHGAP10* in whole cell lysates in *PTEN*-expressing and -deficient cells, shown in new Figure 1---figure supplements 4-8. While we did find expression differences in total lysate, we found proportionately greater differences in juxtamembrane localization of *β-Arrestin1* and *ARHGAP10*, between *PTEN*- expressing and-deficient cells particularly after LPA stimulation. These findings indicate that *PTEN* synergizes with LPA in active membrane recruitment of *β-Arrestin1*. In transfection experiments of GFPtagged -C2 and -C2-MCBR3, we now include separate panels for GFP that show equivalent transfection efficiency and expression levels. Appropriate loading controls were used. We found very low concentrations of *ARHGAP10* with in the cytosolic fraction, in all of our experiments. We loaded equivalent membrane and cytosol fractions in immunoblots and CoIPs. These points have been added to the new manuscript.

> *4) In a related note, the loss of PTEN may simply change the expression levels of β arrestin and ARHGAP10 and not their membrane localizations. This possibility is supported by many data (intensity of β arrestin in [Figure 1C](#fig1){ref-type="fig"}, Western data for total β arrestin expression in cells expressing C2 in [Figure 3D](#fig3){ref-type="fig"}, and increased intensity of β arrestin and decreased intensity of ARHGAP10 in C2-expressing 3D organoids in [Figure 5A-D](#fig5){ref-type="fig"}).*

This important criticism has been partly addressed in our response to point 3. While expression levels differ between *PTEN*-expressing and -deficient total cell lysates, there are greater differences in membrane localization between *PTEN*-expressing and -deficient cells after LPA stimulation. Furthermore, the *PTEN* C2 domain CBR3 interfacial membranetargeting loop is essential for *PTEN/β-Arrestin1/ARHGAP10* scaffolding and 3D multicellular morphogenesis. *PTEN/β-Arrestin1* morphogeneic effects are mediated by suppression of *ARHGAP10* that is predominantly localized within the crude membrane fraction. Hence, the *PTEN* C2 domain membrane targeting function is crucial for *PTEN* noncatalytic regulation of morphogenenic processes. These points have been discussed in the new manuscript.

> *5) In [Figure 3](#fig3){ref-type="fig"}, the authors show that loss of PTEN decreases β arrestin-ARHGAP10 interaction. Ectopic expression of the C2 domain, but not the MCBR3 mutant, rescues this phenotype. The expression levels of C2 and MCBR3 should be examined to exclude the possibility that they have different expression levels and that is the reason for their distinct rescuing activities. They should also test whether C2 or MCBR3 interacts with the β arrestin-ARHGAP10 complex.*

To address these key points, we have shown equivalent expression of GFP-labelled C2, C2-MCBR3 and control GFP in transfected cells (New [Figure 3B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Notwithstanding the equivalent expression levels, C2 transfection promoted greater *β-Arrestin1-ARHGAP10* binding than C2-MCBR3. We complemented our CoIP studies and showed that the *PTEN* C2 domain binds *β-Arrestin1* and promotes *β-Arrestin1/ARHGAP10* interaction in vivo, using sensitive PLA techniques. To do this we used catalytically inactive full length *PTEN* constructs proposed to have an exposed C2 domain (*PTEN* CS124-T383A) and *PTEN* CS124-A4) (7) but that display differential *β-Arrestin1*-binding capacities (1), as well as C2 and C2-MCBR3 (New [Figures 3C and D](#fig3){ref-type="fig"}; Figure 3---figure supplements 7 and 8) \[also see responses below\]. We also addressed C2 domain binding to the *βArrestin1/ARHGAP10* complex, by PLA. The key concept is that target binding between two colour-labelled proteins or protein complexes can generate a single composite signal (2,3). We have shown strong colocalization of C2GFP (green) and the *β-Arrestin1:ARHGAP10* complex (red) indicated by a composite yellow signal. This signal was not generated by C2-MCBR3-GFP or control -GFP ([Figure 3E](#fig3){ref-type="fig"}). These findings have been discussed in the light of the reviewer's criticism, in the revised manuscript.

> *6) In [Figures 4A](#fig4){ref-type="fig"} through F, the authors show that expression of C2 leads to increases in the amounts of membrane-bound β arrestin and decreases in membrane-bound ARHGAP10 levels in PTEN KD/KO cells. How much C2 and MCBR3 are associated with the membrane fraction? Again, the authors need to show the total expression levels of these proteins.*

To address these essential points, we have included GFP expression data to show relative quantitation of each GFP-tagged protein in cytosol and membrane fractions of *PTEN-*deficient cells ([Figure 4 B and C](#fig4){ref-type="fig"}). Furthermore, relative cytosol and membrane localization of C2-GFP and C2MCBR3-GFP are shown in organotypic cultures, in [Figures 5C](#fig5){ref-type="fig"} and E.

> *7) The increase in β arrestin in the membrane fraction by the expression of C2 shown in [Figure 4D](#fig4){ref-type="fig"} is not observed in [Figures 4G](#fig4){ref-type="fig"} and I.*

To address this concern, we have now repeated the immunoblot and Co-IP studies in membrane fractions of *PTEN*-deficient cells in new [Figures 4G-J](#fig4){ref-type="fig"}. Our repeat experiments in triplicate now show greater *β-Arrestin1* in the membrane fraction, after transfection of C2 and full length *PTEN* but not C2-MCBR3 or *PTEN*-MCBR3.

*Reviewer \#2:*

> *Previous studies have shown that b-arrestin interacts with ARHGAP10 and negatively regulates its GAP activity. Here the authors show that PTEN positively regulates membrane localization of b-arrestin. Consistent with previously reported findings the authors show that the C2 domain of PTEN mediates the interaction with b-arrestin. In addition, the author investigate the biological significance of this pathway using caco2 3D culture system and investigate changes in spindle orientation during cell division and its effect of morphogenesis. This is an interesting study that connects PTEN with ARHGAP10 pathways and adds more insight into the previously known relationship between PTEN and b-arrestin. However, as outlined below, additional insights into the relationship between PTEN and b-arresting/ARHGAP10 interaction would increase the impact of the study.*
>
> *[Figure 1A](#fig1){ref-type="fig"} -- the authors state loss of PTEN results in \"greater b-arresting but lower ARHGAP10 levels in membrane fractions\" but the data presented show a lower b-arrestin and greater ARHGAP10.*

We thank the reviewer for his positive and helpful comments. We apologise if our findings were not wholly clear but our interpretation is that membrane *β-Arrestin1* is higher in Caco-2 than in *PTEN*-deficient Caco-2 Sh*PTEN.* Because of space limitations, we have referred to *Caco-2 ShPTEN* cellsas Sh*PTEN* in immunoblots, which may have caused confusion. We have now provided clearer descriptions in the text and figure legends. As indicated in our response to reviewer 1, we have repeated the studies for [Figure 1A](#fig1){ref-type="fig"} where higher *β-Arrestin1* and lower *ARHGAP10* are shown in membrane fractions of parental *PTEN* -- expressing cells.

> *[Figure 1C](#fig1){ref-type="fig"}: Can the authors show a control membrane protein that can translocate to membrane upon a ligand stimulation irrespective of PTEN levels. This control will rule a non-specific effect of PTEN knockdown that interferes with membrane biology.*

We thank the reviewer for this suggestion and have investigated membrane localization of *E-Cadherin*, mediated by exposure to 1,25(OH)~2~D~3~ (4). We show equivalent 1,25(OH)~2~D~3\ --~ mediated membrane localization of *E-Cadherin* in Caco-2 and Caco-2 Sh*PTEN* cells. We include the localization images ([Author response image 1](#respfig1){ref-type="fig"}). As we already have many figures within the manuscript, we refer to the finding in the main text, as data not shown.

![To investigate effects of *PTEN* on ligand- mediated enhancement of a membrane protein (Reviewer 2, point 2, [Figure 1C](#fig1){ref-type="fig"}), we tested 100nM 1,25 (OH)~2~ Vit D~3~*vs* vehicle only control against membrane recruitment of *E-Cadherin* (4) in Caco-2 and Caco-2 Sh*PTEN* cells.](elife-24578-resp-fig1){#respfig1}

> *The authors should determine changes in RHOA activity and its potential role in the morphogenesis phenotype reported here because of the previously reported relationship between ARHGAP10 and RhoA.*

To address this relevant suggestion, we have now assessed relationships between *β-Arrestin1*, *ARHGAP10* and *RhoA*. We show that *RhoA*-GTP intensity relates directly to *β-Arrestin1* and inversely to *ARHGAP10* expression. Similarly, *PTEN* knockdown suppresses *β-Arrestin*, enhances *ARHGAP10* and suppresses *RhoA-GTP* ([Author response image 2 A,B](#respfig2){ref-type="fig"}). Again, we refer to this finding in the new manuscript as data not shown. Hence, *PTEN* acts as an upstream regulator of both *RhoA* and *Cdc2* GTPases via *β-Arrestin1* and *ARHGAP10*. While understanding of the specific roles of *CDC42* and *RHOA,* their respective tissue-specific GEFS and GAPS (5) and the particular subcellular, cellular and multicellular phenotypes that they control during 3D morphogenesis could greatly alter our comprehension of disease states, we feel that such a mechanistic dissection is beyond the scope of this manuscript.

![2A To investigate effects of the *PTEN/β-Arrestin1/ARHGAP10* cascade on *RHOA* (Reviewer 2; point 3), we assessed *RHOA*-GTP in Caco-2 *vs* Caco2 Sh*PTEN (*Sh*PTEN)* cells (First column).](elife-24578-resp-fig2){#respfig2}

> *The authors show PTEN loss decreases b-arrestin-ARHGAP10 interaction, however it is not clear how loss of PTEN affects the interaction between b-arrestin and ARHGAP10. The authors should provide a clear insight into the mechanistic basis for this observation.*

We provide the following rationale for this important issue in the Discussion:

*"PTEN* interacts via its C2domain with *β-Arrestin1*. \[...\] Collectively, these findings indicate that *PTEN* through its intact C2 domain binds *β-Arrestin1* and promotes *β-Arrestin1/ARHGAP* interactions".

*Reviewer \#3:*

> *The manuscript \"PTEN controls glandular morphogenesis through a juxtamembrane b-arrestin1/ARHGAP10 scaffolding complex\" from Javadi et al., builds on previous molecular data demonstrating that (i) b-arr1 can interact with the C2 domain of PTEN to regulate phosphatase-independent PTEN functions, and (ii) that b-arr1 binds and suppresses the GAP ARHGAP10/21, to reveal that glandular morphogenesis is controlled through juxtamembrane b-arr1/ARHGAP10/CDC42 dynamics. The study adds new knowledge to how PTEN and b-arr1 can coordinately regulate cell polarity in multicellular architecture, and that changes in this complex drives morphological defects in relevant colorectal cancer models. While the work is well done, some critical controls are missing and some mechanistic points could be further developed and discussed to strengthen the findings.*
>
> *In [Figure 1C](#fig1){ref-type="fig"} b-arr1 staining in the PTEN-deficient lines is weak. Enhanced contrast images should also be shown so the reader can more readily analyze the panels. Why is there a discrepancy between the blot data (in [Figure 1A, a](#fig1){ref-type="fig"} small effect on the b-arr1 signal) and the IF data (in [Figure 1C, a](#fig1){ref-type="fig"} large decrease in signal)? The authors also state in [Figure 5](#fig5){ref-type="fig"} that the isolated C2 domain enhanced b-arr1 immunoreactivity and decreased ARHGAP10 immunoreactivity, but do not come back to it in the discussion. Please discuss these findings further.*

We thank the reviewer for his positive comments and important criticisms. We have partly addressed these points in our response to reviewer 1. We have repeated the fractionation studies and immunoblots of [Figure 1A](#fig1){ref-type="fig"} and have conducted membrane localization studies using GFP-tagged *β-Arrestin1* that show *PTEN* effects more clearly. Densitometry differences of *β-Arrestin1* and *ARHGAP10* in membrane fractions of *PTEN*-expressing and deficient cells are statistically significant. There are still some quantitative differences in membrane localization between new [Figures 1A](#fig1){ref-type="fig"} and [Figure 1C](#fig1){ref-type="fig"} that use different experimental methods. These can be attributed at least in part to different timescales of the experimental techniques. [Figure 1A](#fig1){ref-type="fig"} assesses protein accumulation in membrane fractions after 24 hrs culture while [Figure 1C](#fig1){ref-type="fig"} assesses differences at 5 minutes after LPA treatment *vs* control. The point concerning [Figure 5](#fig5){ref-type="fig"} has been partly addressed by our response to reviewer 2 and our PLA studies that investigated *PTEN/βArrestin1/ARHGAP i*nteractions. We have also addressed relevant mechanisms in the Discussion as follows;

*"*C2 domains are phospholipid and protein binding modules involved in recruitment of signalling molecules to specific membrane regions. \[...\]Hence, an intact C2 domain CBR3 loopmay be required for *PTEN* N-terminal promotion of *β-Arrestin1ARHGAP10* binding".

> *In [Figure 3A](#fig3){ref-type="fig"} another gel should be shown for the ARHGAP10 blot in Caco-2 shPTEN cells, as there appears to be a technical issue that would affect quantification. How many times was this experiment performed? The same goes for [Figure 4D](#fig4){ref-type="fig"}. Also, in all coIP experiments in [Figure 3](#fig3){ref-type="fig"}, control experiments should be performed with non-relevant control antibodies. Another issue, in [Figure 3D and F](#fig3){ref-type="fig"}, is that blots should be shown to demonstrate equivalent expression of C2 and C2MCBR3. The same holds for [Figures 4 A](#fig4){ref-type="fig"} and D.*

To address these key points, we have repeated the immunoblots and Co-IPs for [Figures 3A, D, F](#fig3){ref-type="fig"} and [Figures 4A, D, G and I](#fig4){ref-type="fig"} and new quantitation figures. All immunoblots and CoIPs were conducted at least in triplicate. We have included a non-relevant control protein (IgG) in [Figure 3A](#fig3){ref-type="fig"}, as the reviewer has suggested. We have conducted PLA studies to assess interactions with greater sensitivity. In new [Figures 3D, F](#fig3){ref-type="fig"} and [Figures 4A,D,G](#fig4){ref-type="fig"}, we have included immunoblots of GFP to indicate GFP-C2 and GFP-C2MCBR3 transfection efficiency and transgene expression. Please note that in the revised manuscript, some figures have been renamed and [Figure 3D](#fig3){ref-type="fig"} is now new [Figure 3B](#fig3){ref-type="fig"}, [Figure 3F](#fig3){ref-type="fig"} is now new [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}.

> *What is the effect of CBR3 mutation in the FL PTEN in [Figure 4I-J](#fig4){ref-type="fig"}?*

To address this point, we have repeated the CoIP and quantitation studies of [Figure 4I](#fig4){ref-type="fig"} and [Figure 4J](#fig4){ref-type="fig"} to include full length *PTEN* with the CBR3 mutation (*PTEN*-MCBR3). In that revised figure, we show that transfection of C2 or full length *PTEN* induced higher *β-Arrestin1/ARHGAP* interactions than C2-MCBR3 and *PTEN*-MCBR3 than respectively. We found that *PTEN*-MCBR3 did enhance *β-Arrestin1:ARHGAP10* binding in PLA assays but differences were not significant in CoIps. This may be a reflection of the greater sensitivity of PLA assays or the greater number of PLA experimental results for analysis (n = 35 cells for PLA *vs* single immunoblot densitometry values in triplicate) or both factors. The finding has been discussed in the manuscript text.

> *The authors use a previously characterized cell-permeant disruptor peptide to inhibit the b-arr1/ARHGAP10 complex (Anthony et al., MCB 2011). It would also be interesting to test the effect of inhibiting the b-arr1/PTEN complex, which would additionally strengthen the molecular data. One way to do this would be to use previously characterized PTEN mutants that display differential binding to b-arr1 in a phosphatase-independent setting (Lima-Fernandes et al. EMBO J 2011). In a catalytically dead context (C124S), mutation of Thr 383 to Ala increases b-arr1/PTEN binding whereas mutation of Ser380, Thr382, Thr 383 and Ser385 altogether to Ala decreases b-arr1/PTEN binding. If the authors can recapitulate this difference in binding, in their colorectal model systems, the effect of reintroducing these mutants on active Cdc42 levels and morphology phenotypes could be compared.*

To address this excellent suggestion, we have obtained the *PTEN* mutants to which the reviewer refers, from our collaborator Dr Mark Scott, Inserm, Paris. We have confirmed the differential *β-Arrestin1* binding to these mutants in PLA studies ([Figure 3 C-E](#fig3){ref-type="fig"}) and have assessed their effects on *Cdc42* activation, in transfection studies. Unfortunately, we cannot test effects of these mutants upon morphology of our *PTEN-*deficient 3D model. This is because our Caco-2 Sh*PTEN* model was generated by stable expression of *PTEN* ShRNA targeted against the N-terminal coding region. Hence, we cannot express *PTEN* C124S-T383A in our Caco-2 Sh*PTEN* cells. Conversely, transfection of wt Caco-2 cells with *PTEN* CS-A4 would not bind endogenous *β-Arrestin1* and could not competitively inhibit endogenous *PTEN/β-Arrestin1* binding. This omission represents the only reviewers' criticism that we were unable to address and it is because of intrinsic limitations of our model. We have however shown that *PTEN* C2 binds and promotes membrane recruitment of *β-Arrestin1,* enhances *β-Arrestin1:ARHGAP10* binding, upregulates *CDC42-GTP* and rescues morphogenic processes including spindle orientation, AM alignment and 3D multicellular gland formation. We show that phosphatase-independent *PTEN* binding of *β-Arrestin1* an unmasked C2 domain enhances *CDC42* activation. Conversely, suppression of *β-Arrestin1:ARHGAP10* binding by the targeted peptide, inhibited *CDC42* activation and disrupted morphogenesis. Hence, the case for *PTEN* phosphatase-independent regulation of morphogenesis through *β-Arrestin1:ARHGAP10* interaction and *CDC42* activation is robust.

> *The discussion should be expanded to give a more comprehensive overview on GPCR/b-arr/PTEN regulation and the functional effects previously attributed to the b-arr1/ARHGAP10 (stress fibre formation) and PTEN interactions (cell proliferation and migration).*

We have now expanded the Discussion to include these points as follows:

*"PTEN* is frequently downregulated in human colorectal and other cancers, even in the absence of genetic loss or mutation. \[...\]By modulation of *PTEN-β-Arrestin* interactions, GPCRs may influence *β-Arrestin*dependent GTPase activation, cytoskeletal dynamics, directional cell migration and cancer susceptibility"

> *It would also be good to have a schematic of PTEN showing the C2 domain and the sequence of the mutant that was generated to create MCBR3. Similarly, a schematic of ARHGAP10, with the b-arr1 binding site and sequence of disruptor peptide used would be good to have.*

We have previously published a schematic of PTEN showing the C2 domain as well as PTEN-MCBR3 and C2-CBR3 (15). However, we now include a revised schematic ([Figure 4A](#fig4){ref-type="fig"}) that is [not]{.ul} a direct copy of the previously published figure. We obtained the MCBR3 mutants from Dr Nicholas Leslie, in Dundee who mutated 5 lysines in the CBR3 to Ala (26) as described by Lee et al. (10). We have confirmed this sequence order and include a description of the mutant sequence. We also include a schematic of ARHGAP10, with the b-arr1 binding site and sequence of disruptor peptide used, as the reviewer has suggested ([Figure 6B](#fig6){ref-type="fig"}).

*Reviewer \#4:*

> *In this manuscript the authors investigate the role of the C2 domain of PTEN in controlling CDC42-dependent processes (i.e. spindle orientation and lumen formation) in Caco-2 3D cultures via regulation of β-Arrestin1/ARHGAP10 interaction. Because the PTEN C2 domain alone is sufficient to mediate the effect of PTEN the authors conclude that in this context PTEN functions as a scaffold rather than via its lipid modifying activity.*
>
> *The non-catalytic function of PTEN via β-Arrestin1/ARHGAP10 is a novel an interesting result that is well supported by transfection (i.e. KD and rescue) experiments. There are however aspects of the mechanistic regulation of the proposed scaffolding function that are less convincing. Specifically, the co-IP experiments shown in [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} are not as convincing as the spindle orientation and lumen formation data. This may be due to technical limitations, co-IP/WB approaches are hardly quantitative and make detention of subtle differences difficult. It would be best if the authors could revisit their protein interaction experiments using other complementary methods such as proximity ligation, split systems or FRET.*

We thank the reviewer for these excellent suggestions and have now conducted proximity ligation assays that show differential *β-Arrestin1* binding *to PTEN vs PTEN*-MCBR3 and to C2 *vs* C2-MCBR3. Furthermore we show differential effects of *PTEN vs PTEN*-MCBR3 and C2 *vs* C2-MCBR3 on *β-Arrestin1/ARHGAP10* interactions ([Figure 3](#fig3){ref-type="fig"}). To validate the proximity ligation data we included two *PTEN* mutant constructs (*PTEN* CS-T383A and *PTEN* CS-A4) that we obtained from our collaborator, Dr Mark Scott, Inserm, that respectively have or do not have of *β-Arrestin1* binding capacity. As indicated in the response to reviewer 3, bioluminescence resonance energy transfer (BRET) analyses of CS-T383A and PTEN CS-A4 show different conformations consistent with proteinbinding differences. These findings support the main finding of our manuscript that *PTEN* C2 domain controls threedimensional multicellular morphogenesis through juxtamembrane *β-Arrestin1/ARHGAP10/CDC42* scaffolding.

\[Editors\' note: the author responses to the re-review follow.\]

*Summary:*

> *The editors and the reviewer agreed that your work reporting the new functions of PTEN you describe vis-a-vis interactions with β-arrestin, ARHGAP21 interesting. However, a number of further points have been raised. We would like to invite you to revise the manuscript accordingly.*
>
> *I would also like you to proofread the entire manuscript and figures carefully.*

We thank the editors and reviewers for their supportive comments and very helpful criticisms that have enabled substantive improvement of the manuscript. After careful proofreading, we have corrected all typing and other errors in the text, figure legends and figures. We address reviewers and editors specific comments with an itemised response, outlined below. In addition, we have also revised most figures to improve perception of detail. Alterations include new experiments and enlarged image sizes of β-Arrestin1 colocalization with a plasma membrane marker within new [Figure 1](#fig1){ref-type="fig"}. We also include line scans and 2 Z-stack reconstructions. In [Figures 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"}, we better show spindle alignment by use of solid and interrupted white arrows to show the angles of spindle orientation towards gland centres, in high power spindle views. In [Figures 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"} we have enlarged panel sizes to better show detail in proximity ligation assays (PLA) and organoid studies respectively. In all of the blots we have included molecular weight indicators as recommended. We include total lysate expression of β-Arrestin1 and ARHGAP21 in blots as recommended. In quantitative graphs, we express β-Arrestin1 and ARHGAP21 protein levels in membrane fractions as a ratio of total expression values in cell lysates, as recommended. We clearly indicate this change in Y-axis graph labels. To aid clarity, we have repeatedly used the terms Caco-2 ShPTEN (ShPTEN), PTEN-/- HCT116 (PTEN -/-) and PTEN C2 (C2) to indicate the cellular or gene origins of abbreviated forms of ShPTEN, PTEN -/- and C2 respectively.To aid visibility, we have also placed just one 20 µm scale bar in one image of each composite figure, as recommended.

*Essential revisions:*

> *Point 2. [Figure 1C](#fig1){ref-type="fig"} and supplement. The image quality is still low, perhaps because of the pdf size, but some images also appear out of focus. They are not of adequate quality to show plasma membrane localization of β-arrestin1 or any change in its localization with and without PTEN expression or LPA stimulation. The higher magnification areas and use of β-arrestin1-GFP do not help here. Inclusion of a membrane marker is essential (e.g. GFP-K-Ras C-terminus) to indicate where the plasma membrane is. Although the authors rule out quantification, it is possible to draw line scans across the cells, and determine whether or not β-arrestin1 co-localizes with the plasma membrane marker. Confocal z-stacks might help to indicate the localization better. Why are the scale bars in a different place in each image? All images should be at the same scale, and then one scale bar in one image is adequate.*

We have followed reviewers' advice in points 2 and 3 for these essential revisions. We used wheat germ agglutinin (WGA) as a plasma membrane marker) and show colocalization of β-Arrestin1-mCherry with Alexa- 488-labelled WGA in PTEN-expressing or -deficient cells, with or without LPA stimulation. As recommended, we also use line scans and Z-stack reconstructions. We use mCherry only controls. To improve visibility, we have also placed just one 20 µm scale bar in each composite figure, as suggested.

References

1\. Lima-Fernandes E, Enslen H, Camand E, Kotelevets L, Boularan C, Achour L, et al. Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins. Embo J. \[Research Support, Non-U.S. Gov\'t\]. 2011 Jul 6;30(13):2557-68.

2\. Agrawal A, Deo R, Wang GD, Wang MD, Nie S. Nanometer-scale mapping and single-molecule detection with color-coded nanoparticle probes. Proc Natl Acad Sci U S A. \[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\'t\]. 2008 Mar 4;105(9):3298-303.

3\. Huang B, Babcock H, Zhuang X. Breaking the diffraction barrier: superresolution imaging of cells. Cell. \[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\'t\]. 2010 Dec 23;143(7):1047-58.

4\. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol. 2001 Jul 23;154(2):369-87.

5\. Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiological reviews. \[Research Support, Non-U.S. Gov\'t Review\]. 2013 Jan;93(1):269-309.

6\. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A. 2009;106(2):480-5.

7\. Raftopoulou M. Regulation of Cell Migration by the C2 Domain of the Tumor Suppressor PTEN. Science. 2004;303(5661):1179-81.

8\. Lima-Fernandes E, Misticone S, Boularan C, Paradis JS, Enslen H, Roux PP, et al. A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. Nat Commun. \[Research Support, Non-U.S. Gov\'t\]. 2014;5:4431.

9\. Corbalan-Garcia S, Gomez-Fernandez JC. The C2 domains of classical and novel PKCs as versatile decoders of membrane signals. BioFactors (Oxford, England). 2010;36(1):1-7.

10\. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99(3):323-34.

11\. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol.

2004;265(1):23-32.

12\. Galvez-Santisteban M, Rodriguez-Fraticelli AE, Bryant DM, Vergarajauregui S, Yasuda T, Banon-Rodriguez I, et al. Synaptotagmin-like proteins control the formation of a single apical membrane domain in epithelial cells. Nat Cell Biol. 2012 Jul 22;14(8):838-49.

13\. McConnachie G, Pass I, Walker SM, Downes CP. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J. 2003;371(Pt 3):947-55.

14\. Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007;17(2):115-25.

15\. Jagan IC, Deevi RK, Fatehullah A, Topley R, Eves J, Stevenson M, et al. PTEN phosphatase-independent maintenance of glandular morphology in a predictive colorectal cancer model system. Neoplasia. \[Research Support, Non-U.S. Gov\'t\]. 2013 Nov;15(11):1218-30.

16\. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J. 2004;379(Pt 2):301-7.

17\. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.

18\. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403-14.

19\. Song P, Zhang M, Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem. \[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\'t\]. 2009 Jun 19;284(25):17120-8.

20\. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012 May;13(5):283-96.

21\. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci U S A. \[Research Support, N.I.H.,

Extramural Research Support, Non-U.S. Gov\'t\]. 2008 Jul 22;105(29):9988-93.

22\. Urs NM, Jones KT, Salo PD, Severin JE, Trejo J, Radhakrishna H. A requirement for membrane cholesterol in the β-arrestin- and clathrin-dependent endocytosis of LPA1 lysophosphatidic acid receptors. J Cell Sci. \[Research Support, N.I.H., Extramural\]. 2005 Nov 15;118(Pt 22):5291-304.

23\. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, et al. Β-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. \[Research Support, Non-U.S. Gov\'t\]. 2009 Jul;7(7):1064-77.

24\. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem. \[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\'t\]. 2011 Sep 16;286(37):32188-97.

25\. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A. \[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov\'t\]. 2007 Jul 17;104(29):12011-6.

26\. Orchiston EA, Bennett D, Leslie NR, Clarke RG, Winward L, Downes CP, et al. PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6- pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal. J Biol Chem. 2004;279(2):1116-22.

27\. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 2000;60(24):7033-8.

28\. Naguib A, Bencze G, Cho H, Zheng W, Tocilj A, Elkayam E, et al. PTEN functions by recruitment to cytoplasmic vesicles. Mol Cell. \[Research Support, N.I.H., Extramural\]. 2015 Apr 16;58(2):255-68.

29\. Pertz O. Spatio-temporal Rho GTPase signaling -- where are we now? J Cell Sci. 2010 Jun 1;123(Pt 11):1841-50.

30\. Durgan J, Kaji N, Jin D, Hall A. Par6B and atypical PKC regulate mitotic spindle orientation during epithelial morphogenesis. J Biol Chem. 2011 Apr 8;286(14):12461-74.

[^1]: These authors contributed equally to this work.
